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Aims: The overall aim of this thesis is to describe and evaluate hereditary uterine cancer 
syndrome both independent of and in relation to hereditary patterns of Lynch and/or Cowden 
syndrome for the purpose of recognizing and defining a unique pattern of familial uterine 
cancer. 
The thesis also aims to determine whether the TERT-CLPTM1L region is a novel risk locus 
for endometrial cancer. 
Finally, we aim to assess expression of two mitochondrial proteins, PGC1 and VDAC1, 
within the same population, as well as to consider the impact of different dietary and lifestyle 
factors on prognosis for endometrial cancer (EC).  
 
Materials and methods: All studies are retrospective and based on a cohort population of 
women who were diagnosed with endometrial cancer and underwent surgery at Karolinska 
Hospital, Stockholm, Sweden, between January 1, 2008 and March 31, 2012. 
All women who agreed to participate completed questionnaires, one concerning family 
history of cancer and the other regarding personal health history including comorbidity, 
parity, medications, lifestyle and dietary habits. Data on clinicopathological variables were 
obtained from the Take Care medical records system.  
In study I we constructed pedigrees based on the questionnaires with verification by 
telephone interview, assessed the relative frequencies of various cancers among family 
members and compared those with the general Swedish population in 1970 and 2010.  
 
Study II entails a collaborative effort, known as the Endometrial Cancer Association 
Consortium (ECAC), in which 5591 women of European ancestry with a history of 
histologically verified diagnosis of endometrial cancer were enrolled into 11 separate studies 
conducted in Western Europe, North America, and Australia. The Swedish contribution to 
this multicenter study derives from the Registry of Endometrial Cancer in Sweden 
(RENDOCAS), which is a hospital-based registry of consecutively occurring EC cases. The 
study included 262 cases of EC taken from the same group as Study I and enrollment 
continued until 2011. In addition to the above information, DNA samples for each patient 
were obtained from peripheral blood.  
 
In Study III, both tumor and adjacent benign tissue were analyzed using 
immunohistochemistry and subsequently scored to assess PGC1 and VDAC1 expression in 
 
 
both types of tissue and to correlate these findings with clinical data.  
 
In Study IV a smart machine learning model, Random Survival Forest, was used to analyze 
the extensive data and correlate them with prognosis for endometrial cancer. 
 
Results: In Study I we found an increased prevalence of EC among our study population 
compared with the general population in Sweden in 1970 and 2010. Lynch syndrome, as 
defined according to the Amsterdam II criteria, was found in 7 families. In all, 13% of index 
patients had at least one relative with EC and these families showed a tendency for more 
cases of early onset cancer among family members.  
 
In study II, data concerning single nucleotide polymorphisms (SNPs) taken from the 5p15 
region were available from 4401 cases and 28 758 controls. Using logistic regression, we 
found three imputed SNPs (rs7705526 (in SNP set 1), rs13174814  (SNP set 2) and 
rs62329728 (SNP set 3)) that each showed evidence of being independently associated with 
disease for which the respective ORs were 1.11, 0.87 and 1.27 by unconditional analysis. The 
linkage disequilibrium (LD) between these three SNPs is weak, which further suggests that 
they represent independent risk factors for endometrial cancer. When comparing with data 
taken from the cancer genome atlas (TCGA), we were able to identify higher expression of 
TERT-CLPTM1L RNA in EC tissue than found in normal tissue.  
 
Study III found that both PGC1 and VDAC1 showed significantly lower expression in 
tumor tissue compared with benign tissue. We also observed a correlation trend indicating an 
association between low PGC1a expression and shorter time to death among patients in the 
FIGO I group.   
 
The study IV analysis revealed that consumption of fried potatoes and carbonated soft drinks 
is higher among women with recurrent endometrial cancer and death.  
 
Conclusions: Our study found an overrepresentation of EC among first- and second-degree 
relatives, as well as first cousins of endometrial cancer patients, when compared with the 
general population. Young age of onset and occurrence of multiple cancers in families with 
EC suggest the presence of additional factors relating to hereditary EC syndrome. We 
emphasize the importance of accurate diagnosis, with referral for genetic counseling, and 
improved surveillance of individuals at high risk for EC.   
 
 
In study II we succeeded in uncovering a novel risk locus for EC and implicated three novel 
independent genetic variants within the 5p15 locus (already associated with several cancers) 
that increase risk of developing EC. Overexpression of TERT in cases of EC when compared 
with normal tissue suggests a potentially important role for this gene in tumorigenesis. Our 
findings may account for about 0.5% of the relative risk for familial EC.  
 
Study III found downregulation of both PGC1 and VDAC1 in malignant tissue, as well as 
a correlation between low PGC1a expression and shorter time to death among patients in the 
FIGO I group.  This correlation has important clinical implications since these patients are 
treated exclusively by surgery. Should lower expression of PGC1a correlate with increased 
risk of recurrence, new therapeutic strategies may be required. 
 
In study IV we observed that consumption of fried potatoes and sweetened carbonated 
beverages is associated with higher risk of recurrence and death from EC. Dietary 
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1.1 INCIDENCE AND MORTALITY RATE 
1.1.1 Incidence 
Endometrial cancer (EC) is a predominant gynecological malignancy in the western world [1], 
which has gradually increased in incidence over recent decades while age of onset has decreased 
[2]. EC is driven by a variety of factors, including abnormal genetic and epigenetic alterations, 
as well as environment. Obesity, diabetes, hypertension and lack of physical activity have been 
well-studied as risk factors and continue to pose a challenge in western countries where their 
prevalence is increasing. The annual incidence in developed countries is between 19 and 25 
cases per 100 000, while in developing countries, the incidence is much lower at 1 to 4 cases 





Figure 1. Estimated age-standardized Incidence rates of endometrial cancer in 2020. [4]. Global Cancer 
Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: 









1.1.2 Mortality rate 
The risk of developing EC increases with age; more than 90% of cases presenting in peri- and 
postmenopausal women, with peak incidence between the ages of 50 and 60[5]. EC is often 
diagnosed at an early stage, since symptoms such as abnormal vaginal bleeding present early, 
for which reason there is often a favorable prognosis with an overall 5-year survival rate greater 
than 80% [1]. In 2020, EC claimed the lives of 345 women in Sweden, making it the eighth 
leading cause of cancer deaths in the country and the second leading cause of death from 




Figure 2. Estimated age-standardized Mortality rates of endometrial cancer in 2020[4].  
Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 
Available from: https://gco.iarc.fr/today, accessed [30 Mars 2021] 
 
1.2 ETIOLOGY 
EC arises from the endometrial layer that lines the uterine cavity and is traditionally classified 
into two subtypes based on clinical, pathological, and molecular criteria: Type I, endometrioid, 
and Type II, non-endometrioid. EC must be distinguished from uterine sarcoma, which most 
commonly arises from either connective tissue or from the muscle layer [6]. Type I accounts 




Type I is hormone-sensitive, correlates with high levels of unopposed estrogen, and most 
commonly affects postmenopausal women. Type II, in distinction to Type I, is not hormone 
sensitive and includes diagnoses such as serous carcinoma, carcinosarcoma (extremely poorly 
differentiated carcinomas), clear cell cancers, and others [1]. Type I tumors are endometrioid 
carcinomas (EECs) that bear a morphological resemblance to normal endometrial tissue when 
well differentiated and are often associated with or follow endometrial hyperplasia. Mucinous 
adenocarcinoma, classified as a Type I endometrial lesion, is quite rare (<5%). Tumor growth 
is usually confined to the uterus, the histological grade is generally low, and cure is usually 
achieved through hysterectomy. In contrast, Type II endometrial carcinomas tend to occur 
among postmenopausal women with atrophic non-neoplastic endometrium. These generally 
high-grade serous or clear cell carcinomas are referred to as non-endometrioid carcinomas 
(NEECs). They are non-estrogen dependent, and etiologically are believed to originate from 
lesions referred to as intraepithelial carcinoma. Clinically, NEECs often demonstrate aggressive 
behavior.  
Molecular data also help to distinguish between the subtypes. Typically, the predominant 
genetic mutations associated with type I etiology include PTEN (phosphatase and tensin 
homolog), PIK3CA KRAS2, CTNB1 (b-catenin-gene), and LMH1 genes, as well as 
microsatellite instability. In contrast, Type II EC is characterized by p53 mutations and 
HER2/neu [7, 8]. 
Furthermore, the genetic alterations that distinguish EECs from NEECs differ from one another 
[5]. The Cancer Genome Atlas (TCGA) Research Network used array and sequencing-based 
technologies to characterize the genomic changes typifying EC by exploring the integrated 
genomic, transcriptomic, and proteomic characteristics in 373 cases of endometrial carcinoma. 
EC can be grouped into four categories based on combinations of somatic nucleotide 
substitutions, microsatellite instability (MSI), and somatic copy number alterations (SCNAs), 
figure 3: 1) POLE ultra-mutated, 2) microsatellite instability, hypermutated 3) copy-number 
low, and 4) copy-number high. Certain genomic features have been identified that are common 
to serous EC, ovarian serous carcinoma and basal-like breast carcinoma[9].   
Most low-grade (FIGO grades 1 and 2) EECs can be mapped to the copy number low and MSI-
H categories, while Grade 3 EEC can be found in any category. EEC is generally associated 
with the endometrioid genomic profile, with presence or lack thereof of the TP53 mutation or 
high copy number alterations. In contrast, serous carcinomas are characterized by 














Figure 3. The genomic classification according to TCGA. Figure reproduced with permission 
 
Moreover, the proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) further 
developed the TCGA classification system to facilitate its application. Under this system, EC 
cases are divided into four subgroups based on a combination of protein expression and 
mutations [11-13].  
As follows. First, immunohistochemistry (IHC) analysis is applied to investigate occurrence of 
the mismatch repair proteins PMS2 and MSH6. The next step is to evaluate potential POLE 
mutations, and finally assessment for aberrant expression of p53 using IHC to yield 
p53abnormal and p53wild type. 
 









1.3 RISK FACTORS 
Risk factors associated with EC, especially of the endometrioid type, have been well defined 
and involve identifiable endogenous or exogenous sources of unopposed excess estrogen. 
The endometrial tissue undergoes a number of dynamic changes over the course of a woman's 
lifetime. Because estrogen is a steroid hormone, it stimulates differentiation and 
decidualization, thereby promoting endometrial cell growth through both genomic and non-
genomic mechanisms. The process entails binding to the estrogen receptor, which modulates 
transcription of a variety of proteins. In addition, estrogen may indirectly activate various 
pathways through non-genomic processes [14]. Moreover, the ovaries are the primary estrogen 
producers in premenopausal women, while later in life, peripheral tissues convert androgens to 
estrone and estradiol under the influence of the aromatase enzyme [15]. 
 
1.3.1 Overweight and obesity 
Endometrial cancer patients typically have a clinical profile that includes high body mass index 
(BMI), generally defined as overweight (BMI 25–30) or obese (BMI 30), and often have signs 
of metabolic syndrome, including hypertension and diabetes. Globally, overweight and obesity 
continue to increase, both in developed and undeveloped countries. In the US, for example, by 
2010 no state had a prevalence under 20%, with most hovering around 30%  [16]. High BMI is 
usually associated with favorable prognostic indicators of EC, including low histological grade, 
endometrioid histology, and a tendency for identification at an early stage. Women with 
metabolic syndrome are at a 1.89 relative risk (RR) for developing endometrial cancer [1]. One 
population-based case-control study of 668 patients examined the association between longtime 
overweight and endometrial cancer and found that women with chronic OW/obesity were at 
almost five times greater risk of developing EC. 
The presence of such risk factors may also correlate with earlier onset of disease [17].  
 
1.3.2. Diabetes mellitus 
Type II diabetes mellitus (DM) has long been considered to be an independent risk factor, with 
an approximate RR of 2.0. Because obesity is common with type II DM, it may represent a 
confounding risk factor, raising the question of the independent role of DM [1]. 
Because of the high correlation between obesity and insulin resistance, many studies have 
focused on investigating the role of DM as an independent risk factor.  One comprehensive 
meta-analysis of 29 studies consistently found a nearly twofold increase in risk of endometrial 
cancer in women with DM. The potential benefits of metformin have also been well studied 
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and while  one meta-analysis indicated a reversible effect on hyperplasia, others showed no 
such benefits, though all demonstrated improved overall survival (OS) and a reduction in risk 
of recurrence [18, 19].  
 
1.3.3 Unopposed estrogen 
Hyperestrogenism is also related to other identified risk factors, such as unopposed estrogen 
therapy (especially with duration of treatment longer than five years), as well as to estrogen-
producing tumors, such as ovarian granulosa cell tumors and theca cell tumors, each of which 
may increase risk of developing EC by as much as 20%. Early onset menarche (age <12 years) 
and late menopause (age >55 years) may double the risk for occurrence of EC [1]. 
Nulliparity is also a recognized risk factor.  In contrast, among women who have given birth, 
data suggest a 40% reduction in risk for EC [20]. Polycystic ovarian syndrome (PCOS) is often 
associated with chronic anovulation and possible infertility, once again raising the issue of 
unopposed estrogen, since it is associated with a nearly threefold increased risk of EC (OR 
2.79–2.89)[21]. However, as in the case of diabetes, obesity may once again be a confounding 
factor [1]. 
Hormone replacement therapy (HRT) to treat menopause is one source of exogenous estrogen 
among postmenopausal women. Unopposed estrogen has shown a correlation with increased 
risk of EC even when taken for less than five years [22]. Estradiol stimulation of endometrial 
proliferation is both time- and dose-related, as shown by many studies [23], whereas use of 
continuous-combined (cc) HRT with synthetic progestins reduces this risk, as shown in a 
systematic review of 31 studies [24]. However, long-term use (>5 years) of estrogen combined 
with micronized progesterone increases the absolute risk of developing EC [25, 26]. 
Nevertheless, a more recent systematic review demonstrates a significant protective effect from 
combined therapy when a more appropriate dose regimen is used [27] In summary, all studies 
show a correlation between EC and HRT, where type of progesterone (synthetic or micronized), 
dosage and regimen each may play a pivotal role.    
 
1.3.4 Other risk factors 
Adult-attained height: this has been implicated by several studies as a risk factor for EC. A 
direct biological explanation is unlikely, for which reason the genetic and environmental factors 
that affect female growth are likely linked to the risk of developing EC [20]. 
Ethnicity: black women of non-Hispanic are at significantly higher risk for developing and 





Genetics: A familial association with EC has been found in about 5% of cases, though the 
remaining 95% are essentially sporadic. Among younger women, genetic predisposition is the 
most significant risk factor. Lynch syndrome as a monogenic cause of EC has been extensively 
studied [17]. However, other genetic risk factors related to inheritance, including obesity and 
high BMI, are common issues that impact risk for developing EC [29]. 
Smoking: A variety of studies have shown that smoking reduces risk of EC, likely due to 
antiestrogenic properties. The risk of developing EC is lower among both current and former 
smokers than among never smokers [20]. 
Physical activity: Physical activity has demonstrated an inverse association with risk of 
developing EC [20, 30], while also improving survival among those who develop this diagnosis, 
thereby underscoring both a preventive and therapeutic role [31, 32].  
Hypertension – Even after adjusting for confounders such as BMI, smoking, oral contraception 
and parity, hypertension appears to be associated with a risk of EC. Although the exact 
pathological mechanism has not been defined, the suggestion is that chronic hypertension 
inhibits apoptosis and promotes cellular aging [20]. 
 
1.4 TUMOUR CHARACTERISTICS 
EC generally presents early with abnormal uterine bleeding, facilitating diagnosis at an early 
stage, at which time surgical treatment alone is usually curative [33]. Meticulous preoperative 
staging of early EEC, however, is necessary to avoid over or undertreatment with surgery. 
1.4.1 Histopathology and grade 
According to the WHO/International Society of Gynecological Pathology, EC may be 
histologically classified into one of two categories: adenocarcinoma or carcinosarcoma. 
Adenocarcinoma can be further subdivided into serous, mucinous, endometrioid, clear cell, and 
mixed tumors. Under the FIGO system, endometrioid carcinomas may be histologically 
classified using a three-tiered grading system based on degree of differentiation: well 
differentiated, moderately differentiated and poorly differentiated. On pathology, EC may 
manifest as a polypoid, plaque-like, or extensively infiltrating mass. EC may spread to involve 
the adnexa, parametrium, distal uterus, and the cervix. Histopathological grading of 
adenocarcinoma is important from a prognostic standpoint. The proportion of solid to glandular 
components can be used to describe three architectural grades [5]. 
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• Grade 1 (G1): well-differentiated, less than 5% of nonsquamous, solid growth pattern. 
• Grade 2 (G2): Moderately with 6-50%  nonsquamou, solid growth pattern. 
• Grade 3 (G3): Poorly differentiated, greater than 50%  nonsquamous, solid growth 
pattern. 
• Serous and clear cell tumours are always classified as grade 3, though this assessment 
does not address squamous epithelial differentiation. 
•  
1.4.2. FIGO staging and classification 
In 2009, a surgical staging system for endometrial cancer was revised based on the earlier 
International Federation of Gynecology and Obstetrics (FIGO) system (table 1) [34]. Surgical 
staging is the most important factor for prognosis and serves as a guide for treatment. Stage I 
tumors are confined to the uterine corpus. The stage I A, B, and C subgroups are based on 
depth of myometrial invasion. Stage II tumors are defined by presence of endocervical gland 
infiltration, while stage III entails regional spread. Stage IV is defined by the presence of 
distant metastases such as bladder or rectal involvement. The combination of surgical staging 
and histological grading provides a comprehensive assessment, divided into low, moderate, 
and high-risk categories [35]. 
 
Table 1. FIGO staging system for EC, 2009 [35] 
Stage I Tumor confined to the corpus uteri 
   IA No or less than half of the myometrium 
   IB Invasion to or more than half of the myometrium 
Stage II Tumor invades cervical stroma, but does not extend beyond the uterus 
Stage III Local and /or regional spread of the tumor 
   IIIA Tumor invades the serosa and/or adnexa 
   IIIB Vaginal and/or parametrial involvement 
   IIIC Metastases to the pelvic and/or para-aortic lymph nodes 
     IIIC1 Positive pelvic nodes 
     IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph nodes 
Stage IV Tumor invades bladder and/or bowel mucosa, and/or distant metastases 
   IVA Tumor invasion of bladder and/or bowel mucosa 





1.5 HEREDITARY SYNDROMES AND GENTICS 
1.5.1 Lynch syndrome 
Lynch syndrome (LS), previously known as Hereditary Nonpolyposis Colon Cancer (HNPCC), 
is a hereditary autosomal dominant disorder with a mendelian inheritance pattern; the disorder 
is also associated with a high risk of endometrial cancer. LS is one of the more common 
hereditary disorders that predisposes carriers to cancer [36], for which the underlying 
mechanism involves germline mutations in DNA mismatch repair genes (MMR). As far back 
as 1895, Warthin observed a familial cluster of cancer cases that were subsequently described 
by Henry Lynch in 1966 [37]. Two families had presented with many cases of similar 
carcinomas, with onset in early age, arousing suspicion of autosomal dominant inheritance. The 
prevalence of LS in the general population is about 0.35% [36]. 
From a genetic standpoint, four MMR genes (MLH1, MSH2, MSH6, or PMS2) are integrated 
into a system that is responsible for recognizing and repairing bases that have been incorrectly 
inserted, deleted, or misincorporated, while also serving to repair DNA damage, situations that 
may arise during DNA replication and recombination [38]. DNA repair is essential for genome 
stability, and mutations in MMR genes lead to increased somatic mutations and microsatellite 
instability. Microsatellites refer to areas of specific sequentially repeating non-coding DNA 
motifs within the genome. Multiple repeats may occur, and microsatellite replication errors may 
arise. Defective MMR genes may induce accumulation of microsatellite replication errors in 
tumors, referred to as microsatellite instability (MSI) [39]. 
LS is associated with many types of cancer that occur early in life (<50 years) and carries with 
it a 46% lifetime risk for developing colorectal cancer, while a 51% risk of endometrial cancer 
has been found. Concerning ovarian cancer, lifetime risk is also high at 15% [40, 41]. The first 
malignancy to present in patients with LS is often EC [42]. Other cancers for which LS carriers 
are at greater risk include brain, gastric, urethral, renal (pelvis), small intestine, and biliary tract 
cancers. About 2% of all EC cases are associated with LS, but unlike sporadically occurring 
EC, LS carriers are generally diagnosed at an earlier stage. The risk among the general 
population of developing early onset EC (<50 years) is 4%-18% [40], while 9% of all women 
diagnosed with EC before age 50 have LS [43], which creates a challenge when considering 
cancer prevention and surveillance programs for women of childbearing age. 
1.5.1.1  Diagnosis and screening methods for LS 
A diagnosis of LS is made according to the revised Amsterdam II clinical criteria and revised 
Bethesda Criteria [39]. 
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Amsterdam II Criteria [44]:  
• At least three relatives with any Lynch syndrome-associated cancer – colorectal (CRC), EC, 
intestinal, ureter or renal pelvis, etc. 
• One should be a first-degree relative of the other two 
• At least two successive generations should be affected 
• At least one should be diagnosed before age 50 
• Familial adenomatous polyposis should be excluded in CRC(s) cases 
• Tumours should be verified by pathological examination 
Revised Bethesda criteria [45] 
• Individual with CRC diagnosed by age 50 
• Individual with synchronous or metachronous CRC or other LS-associated tumours 
regardless of age. 
• Individual with CRC and MSI-H histology diagnosed by age 60 
•  Individual with CRC and more than 1 FDR with an LS-associated tumour, with  
one cancer diagnosed by age 50   
• Individual with CRC and more than 2 FDRs or SDRs with an LS-associated  tumour, 
regardless of age 
Patients must meet all revised Amsterdam II criteria to be eligible for germline genetic testing 
of MMR, but meeting just one Bethesda criterion entitles the patient to laboratory analysis for 
confirmation of MSI which, if positive, qualifies the patient for further DNA germline testing. 
Sensitivity for the Bethesda criteria can reach as high as 90%, but with a positive predictive 
value of only 3%-5%. The initial step in diagnosing LS is to confirm a characteristic mutation 
through tumor immunohistochemistry for MMR and then use PCR to test for MSI. The benefit 
of screening individuals for LS is realized through a reduction in the risk of any attendant 
cancer. For example, colonoscopy screening reduces CRC incidence and improves overall 
survival. Moreover, prophylactic hysterectomy and bilateral salpingo-oophorectomy may be 
indicated to prevent Lynch-associated EC and ovarian cancer [36]. 
More recently, immunotherapy has been used for treatment of MSI tumors, underscoring the 




1.5.1.2 Lynch syndrome and endometrial cancer 
The risk of LS-associated EC is highly mutation-dependent. The highest lifetime risk of 
developing EC is thought to be associated with the MSH2 hand MSH6 with an incidence of 
about 50%, while MLH1 34% and PMS2 24% carry with them a 34% and 24% risk 
respectively. The age of onset is also reduced compared to the general population and is median 
on 49y [47]. 
As in sporadic EC, most LS-associated cases will be diagnosed at an early stage with well-
differentiated histology. Nevertheless, some variation in types of EEC and NEEC have been 
noted among women with LS. 
 
1.5.2 Screening of EC among LS patients 
In 2020, the National Comprehensive Cancer Network (NCCN) published the following 
guidelines to screen for LS among women in the US presenting with EC [48]: 
• EC is often diagnosed at an early stage thanks to early onset of symptoms, for which reason 
women should be encouraged to report abnormal vaginal bleeding or postmenopausal 
bleeding. Endometrial biopsy should be included in the workup. 
 
• Hysterectomy may come into consideration as a risk-reducing option, but it has not been 
shown to decrease mortality though it does reduce incidence. Hysterectomy should be timed 
according to individual risk factors, including comorbidity, family history and specific 
mutations. 
 
• Annual screening with endometrial biopsy is both a highly sensitive and highly specific 
diagnostic procedure, which should begin at age 30-35.  
 
• Transvaginal ultrasound screening for endometrial cancer is not recommended for 
premenopausal women, but can be considered in postmenopausal women, while bearing in 
mind that the procedures is associated with low sensitivity and specificity in 
postmenopausal women. 
1.5.3 Genetics and endometrial cancer  
Endometrial cancer has multifactorial etiology, with an array of genetic and environmental 
factors that play a role in risk of developing the disease. Although Lynch Syndrome, as 
described above, is associated with a high risk for developing EC, it accounts for only about 
2% of cases. Regardless of presence of LS, family history of EC significantly increases the risk 
of developing the disease [49, 50]. 
Regarding family history, a first degree relative with EC doubles the risk of developing this 
disease and risk is even higher if the relative was diagnosed at a young age [51]. 
 
12 
Data regarding the importance of genetic factors in the etiology of this disease can be obtained 
by studying families, twins, and adopted individuals. In the case of monogenic disorders, 
linkage analysis can be used to test for various genetic markers across the entire genome; 
affected individuals in some families always inherit certain risk loci, whereas healthy 
individuals do not. Linkage analysis is reliant on ascertaining specific family structures and 
identifying high-risk genes, which imposes certain limitations. Association studies that search 
for population associations were designed to reveal disease susceptibility genes and are superior 
to the linkage analysis technique for detection of common or weak susceptibility alleles. 
Genome-wide association studies (GWAS) are used to reveal associations between various 
single-nucleotide polymorphisms (SNPs) and specific diseases. Genetic variation in common 
SNPs occurs within the general population and GWAS can be used to compare them and 
associate them with various diseases [52]. Once an association is identified through such 
testing, detailed studies concerning the locus in question can be carried out to ascertain whether 
the SNPs in question are causally related to an increased risk of disease, or whether genetic 
variations in adjacent exons or genes in linkage disequilibrium may be responsible. Additional 
studies are usually carried out on other populations to confirm findings. 
The GWAS technique has been successful in identifying genetic variants that are associated 
with a modest increase in risk for developing different common types of cancer, which suggests 
that some common variants may at least in part be responsible for an elevated risk of familial 
cancer [53]. 
In 2011, Spurdle et al. conducted a genome-wide association study that yielded convincing 
evidence for an association between EC and SNP rs4430796 near the HNF1B gene on 
chromosome 17q [53], later confirmed through a follow-up study focused on how altered 
HNF1B gene expression affects risk of developing EC [54]. 
Subsequently, additional GWAS studies have discovered an additional 16 genetic risk regions 
associated with EC. Additional post-GWAS analyses were able to confirm involvement of these 
genes and pathways in EC carcinogenesis [55-57].  
Figure 5, which summarizes the current state of knowledge regarding hereditary risk, shows a 
model that illustrates the risk associated with various mutations, how common they are, and 





Figure 5. Genetic model suggested for endometrial cancer[55]. The figure is reproduced with permission 
 
 
1.5.4 TERT-CLPTMIL - cancer risk region 
The TERT and CLPTM1L genes are located on chromosome 5p15. TERT encodes the catalytic 
subunit of the enzyme telomerase reverse transcriptase, which is important to remember when 
considering that most cases of cancer in humans involve an increase in cellular proliferation 
associated with telomerase activity [58].  Telomerase permits the replication and proliferation 
of cancer cells in an uncontrolled way and can even enhance their ability to infiltrate tissue and 
metastasize to other organs[59]. CLPTM1L, though not as thoroughly studied, has been 
implicated as serving in an antiapoptotic role in pancreas and lung cancer [60, 61].  While many 
studies suggest an association between various cancers (i.e., brain, breast [62], lung[63, 64], 
prostate[65, 66]) and single-nucleotide polymorphisms (SNPs) in the TERT-CLPTM1L region 





1.6 MOLECULAR FACTORS IN ENDOMETRIAL CANCER 
Since the field of carcinogenesis remains largely enigmatic, much research remains to be done 
on the molecular mechanisms underlying endometrial carcinoma. It is known that the process 
of tumorigenesis entails modification of energy metabolism, as well as a number of other 
mechanisms. The “Hallmarks of Cancer” as set out by Hanahan and Weinberg [68] serve to 
explain and organize carcinogenesis. As such, they include sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion, and metastasis as different traits that the tumor may acquire 
over time. Recent additions to the list include the capacity to reprogram energy metabolism and 
evade immune surveillance.  
The genome instability associated with tumors enables them to acquire the properties listed 
above through mechanisms that activate mutations such as point mutations, deletions, and 
insertions/translocations, with potential impact on oncogenes like KRAS. Because of the 
genomic instability associated with malignancies, tumor suppressor genes such as PTEN may 
become inactivated, thereby undermining their caretaker role in genomic maintenance (DNA 
repair mechanisms, apoptosis, or cell senescence). 
 
  
Figure 6. Hallmarks of Cancer [68] The figure is reproduced with permission 
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Molecular changes within cancer cell mitochondria may be impacted by such metabolic 
modifications, thereby resulting in retrograde signal pathways from mitochondria to nucleus 
[68]. Researchers have found ways to characterize different types of EC according to their 
various molecular alterations. A number of molecular characteristics present in EC have been 
identified, including DNA ploidy, hormone receptors, oncogenes, apoptosis-associated gene, 
cancer suppressor genes, and mismatch repair genes. Such markers have allowed more accurate 
sub-classification, which is helpful in models that predict risk, as well as for individualized 
therapy [9, 69-71]. In addition, molecular data help to classify EC into two subtypes. Type I EC 
is distinguished by diploidy, hormone sensitivity, and microsatellite instability. At the 
molecular level, Type I EC is associated with dysregulation of the PI3K/PTEN/AKT molecular 
pathway, loss of PTEN gene functionality, as well as mutation and hyperexpression of upstream 
tyrosine kinase growth factor receptors. Overall, these changes result in modified uncontrolled 
cell survival and proliferation. However, the Cancer Genome Atlas Research Network   
(CGARN) found that EEC can be microsatellite-stable with a causal relationship to CTNNB1 
mutation, or MSI with MLH1 promoter methylation, including associations with PTEN, TP53, 
KRAS.  
 
Type II tumors, on the other hand, are characterized by aneuploidy and distinguished by 
modification of the CDK2A, TP53, and ERBB2 genes [72]. According to the CGARN, most 
serous and approximately 25% of grade 3 endometrioid tumors demonstrate high somatic copy 
number alteration (SCNA) and low mutation rates, which is consistent with aneuploidy. In 
addition to the TP53 mutations, 22% showed mutations in FBXW7 and PPP2R1A [9]. there 
was also loss of E-cadherin expression and overexpression of HER2 [73]. Downregulation of 
E-cadherin is of special importance in the complex EC invasion mechanism that involves a 
sophisticated chain of biological events, including various modifications in cell adhesion and 
motility. The CGARN classification system [9], revealed genomic characteristics shared in 
common among type I, type II, serous, and the grade 3 endometrioid designations of EC, 
thereby emphasizing the importance of gaining a deeper understanding of the different 
molecular mechanisms underlying EC. Finally, novel molecular marker(s) will need to be 
identified to improve characterization, classification and understanding of EC, thereby leading 







Mitochondria are of crucial importance to cell metabolism. Otto Warburg was awarded the 
Nobel Prize in Medicine and Physiology in 1931 for his work on cell respiration that described 
a glycolysis-dominated metabolic state characterized by lactate production, as is also the case 
in many cancers. He proposed the theory that such cancers may primarily be caused by 
dysfunctional metabolism, a theory ultimately known as “the Warburg effect.” This idea has 
become accepted as one important characteristic of cancer, rather than being an exclusive 
feature [68]. The consumption of glucose by aerobic glycolysis despite the availability of 
oxygen is one important metabolic characteristic of tumors, in contrast to normal cells, which 
primarily depend on oxidative phosphorylation (OXPHOS) [68]. Studies have implicated both 
altered glycolytic and oxidative capacity with the shorter survival associated with ovarian 
carcinomas [74]. 
 
Research is currently underway concerning the mechanisms by which tumor cells reprogram 
various metabolic pathways to satisfy their unique bioenergetic requirements. In order to satisfy 
the large energy requirements needed for rapid proliferation of tumor cells they must maintain 
an available supply of biosynthetic precursor macromolecule building blocks.  
1.6.1.1 Peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1 (PGC1α) 
The last decade has seen advances in identifying a group of cofactors relating to transcriptional 
factors, known as transcriptional coactivators. One such coactivator is called peroxisome 
proliferator-activated receptor-gamma (PPARγ) coactivator 1 (PGC 1α), which is crucial to the 
regulation of the complex mechanisms related to mitochondrial biogenesis and metabolic 
pathways, specifically in relation to cellular energy and homeostasis. 
In the normal situation, PGC1α promotes expression of various nuclear genes to stimulate 
mitochondrial biogenesis, which prioritizes OXPHOS over glycolysis in cellular metabolism 
[75]. Various cancers, including breast, colon [75], and ovary [76], have been observed to have 
lower levels of PGC1α expression, though how level of PGC1α expression relates to tumor 
progression and resistance to chemotherapy is not yet well understood. 
1.6.1.2 VDAC  
Voltage-dependent anion channel type 1 (VDAC1) is a constitutional protein associated with 
the outer mitochondrial membrane, where it helps to regulate mitochondrial import and export 
of ions and metabolites, including ATP and NADH. The regulatory role of VDAC further 
extends to apoptosis involving interactions among different proteins and other factors, such as 
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hexokinase (HK), B-cell lymphoma-2 family (Bcl-2), and glyceraldehyde- 3-phosphate 
dehydrogenase (GAPDH) [77]. Although expression of VDAC in tumors is still insufficiently 
understood, especially concerning endometrial cancer, elevated VDAC levels relative to normal 
fibroblasts have been observed in a number of cancer cell lines. High VDAC gene expression 
has been correlated with poor outcomes in early-stage non-small cell lung cancer [78]. A 
seemingly incongruous observation is that lower expression of VDAC in vitro is associated 
with resistance to apoptosis, even cisplatin-mediated apoptosis [79-81]. 
1.6.1.3 TFAM 
Mitochondrial transcription factor A (TFAM) helps to regulate the number of copies and 
structure of mitochondrial DNA (mtDNA), a process necessary for efficient transcription of 
mtDNA genes. In addition, TFAM helps to regulate mitochondrial biogenesis, a process 
indirectly regulated by PGC1 through its regulation of NRF1-2 [76, 82]. Decreased TFAM 
protein expression was discovered in a multiresistant epithelial ovarian carcinoma by 




1.7 PROGNOSTIC FACTORS 
Since it is known that endometrial cancer has a direct correlation with obesity and high BMI, it 
begs the question of whether dietary habits play a confounder role or act as individual risk 
factors. Because interactions between nutrients are often complex, the role of diet becomes 
difficult to assess with various concerns such as possible diet-related mediation of endogenous 
estrogen, which may affect risk of EC.  
 
1.7.1 Dietary habits  
A number of studies have aimed at finding correlations between dietary habits and EC, 
generally with inconsistent findings. The effect of nutrients concerning EC requires an 
understanding of how insulin and insulin-like growth factor (IGF)-1 influence pathogenesis in 
this disease. Cancer cells demonstrate overexpression of insulin receptors which, even in the 
presence of normal glucose levels, may alter the ability of such cells to obtain an adequate 
amount for growth [49]. Another mechanism involves insulin and IGF-1 activation of cancer 
cell proliferation indirectly through insulin receptor-mediated activation of MAPK and 
phosphatidylinositol-3 kinase. 
 
A 2017 study subjected 27 different studies published between 1995 and 2015 to meta-analysis 
[83]. Authors could show that healthy dietary patterns, as understood by high intake of 
vegetables, fruits, low-fat dairy, olive oil, fish, soy, whole grains, and poultry, decreased the 
risk of EC when compared with a traditional western dietary pattern, as defined by high intake 
of red/processed meat, sweets, high-fat dairy products, potatoes, high-fat gravy, refined grains, 
and a lower intake of fruits and vegetables. 
 
One case-control study from Australia examined dietary patterns consisting of foods that rank 
high on the glycemic index (GI) and/or foods associated with a high glycemic load (GL) [84]. 
The GI ranking of carbohydrate-containing food is determined based on 2-hour blood glucose 
level after consumption, indicating that insulin response correlates directly with GI ranking. In 
part, GL depends on the specifics of GI and yields a value reflecting the quantity and quality of 
carbohydrate contained by a specific food. Circulating blood insulin levels correlate directly 
with digestion of carbohydrates and can be evaluated using both GI and GL measurements [85]. 
The authors of this study report an association between intake of high GI foods and an increase 




1.7.1.1 Acrylamide and cancer risk 
Acrylamide is an organic industrial chemical, a vinyl monomer that has been commercially 
available since 1950. The International Agency for Research on Cancer identified acrylamide 
as a “probable” carcinogen in 1994, based on animal experiments [86]. A 2002 study alerted to 
the presence of acrylamide in foods and how cooking technique affected its formation [87]. The 
association between acrylamide intake and gynecological cancer is thought to be due to 
alteration of sex hormone levels and attendant ability to increase estradiol [52]. A systemic 
review by Adani et al. found an association between acrylamide intake and increased risk of 
endometrial cancer[86]. 
1.7.1.2 Alcohol intake 
Prior studies have addressed the association between alcohol and EC [88]. A large prospective 
study of 68 067 women aged 34-59 years conducted by Je.Y et al. [89] between 1980 and 2010 
examined how long-term alcohol intake affects the risk of developing EC. Findings indicate 
that light alcohol consumption is inversely related to risk of developing EC, while a different 
study showed that women who consumed small amounts of alcohol were at lower risk, while 
high consumption increased risk [90]. 
 
1.7.2 Physical activity  
Physical activity affects the risk of developing cancer and cancer progression through several 
mechanisms, including decreases in insulin levels, estrogen and various sex hormones, as well 
as by improving immune function, and decreasing obesity [91]. Various studies, including 
several meta-analyses, have been undertaken to explore the relationship between physical 
activity and risk and progression of EC. Results have been conflicting, with some studies 
supporting an inverse relationship between exercise and risk of EC, while others were unable 
to confirm this finding. Some of these studies have distinguished between different intensities 
of exercise, varying from regular intensive workouts to household activities [31]. According to 
some of these studies, when reduced physical activity occurs during menopause with an 
increase in BMI, the potential impact on sex hormone levels may contribute to an increased risk 
of EC [92]. Ultimately, the majority of these systemic reviews were unable to demonstrate 




1.8 RISK ASSESMENT 
Over the past decade it has become routine to conduct a preoperative risk assessment, despite 
the lack of accepted definition for “low” or “high” risk relating to endometrial cancer. Risk 
assessment is divided into two sections: preoperative, to assess for risk of lymph node 
metastasis and plan for lymphadenectomy surgery if needed, and postoperative, to assess risk 
of recurrence and identify patients who could benefit from adjuvant therapy. The addition of 
such risk assessment may help to identify patients at high risk of recurrence and thereby 
improve outcome and overall survival should staging wrongly suggest a better prognosis. 
Various assessment systems have been developed over time; PROTEC 1, presented in Table 2, 
is one example [97]. 
 
Table 2. PROTEC1 Risk classification 
Risk EC type FIGO stage Grade Myometrial 
invasion 
Age 
Low  EEC Stage IA G1   
Intermediate  EEC Stage I G1 50%  
Intermediate  EEC Stage I  G2 or G3 <50%  
High Intermediate   G1-2 >50% Age >60 
High Intermediate   G3 <50% Age >60 
High  EEC Stage III -IV    
High  Serous/ 
Clear cell 
Any    
 
Another example is the COG-99 study[98] who divided patients according to the following 
classification:  
 
Table 3. COG-99 risk classification 
Risk EC type FIGO stage Grade Age Risk factors * 
Low  EEC Stage Ia G1-2     
Low-
Intermediate  
      Age<50 < 2 risk factors 
Low - 
Intermediate  
EEC     50-69 < 1 risk factor 
Low - 
Intermediate  
EEC     >70 No risk factors 
High 
Intermediate 
        3 risk factors 
High 
Intermediate 
      50-59 >1 Risk factor 




Any       
* G2 or G3, LVSI, Myometrial invasion >50% 
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Currently, one prominent risk classification system is ESMO [7], table 4. which takes into 
account factors such as FIGO staging, age, depth of myometrial invasion, tumor type, 
differentiation grade and lymphovascular space invasion (LVSI). Because lymphadenectomy 
is often followed by lifelong consequences that negatively impact quality of life among 
endometrial cancer survivors, the procedure should only be undertaken on selected patients. For 
this reason, the procedure is primarily limited to high-risk patients, but may be considered on 
patients at intermediate risk, in part to improve staging accuracy [1].  
 
In Sweden, as for today, preoperative risk assessment encompasses two approaches based on 
the following prognostic risk factors: histological type, FIGO grade and DNA ploidy. About 
25% of patients emerge as being at high risk. A designation of preoperative high risk is 
associated with the following: non-endometrioid type, Figo grade 3, deep myometrial invasion, 
or cervical stromal invasion suspected by ultrasound or MRI, as well as clinical suspicion of 
cervical stromal invasion.  Preoperative low risk: none of the above.  
However, in the future, the vision is that sentinel node biopsy will replace the pre-operative 
assessment. 
 
The next step, as mentioned above, is to conduct postoperative risk assessments in order to 
select patients who are appropriate for adjuvant therapy in order to optimize their treatment to 
improve survival and reduce recurrence. The 2016 ESMP-ESGO-ESTRO consensus 
conference adopted this risk classification system for EEC [7]. 
 
Table 4. ESMO risk classification  




Low I G1-2 <50% negative 
Intermediate I G1-2  negative 
High-
Intermediate 
I G3 <50% neg/pos 
High-
Intermediate 
I G1-2   positive 
High I G3  neg/pos 
High II-IV       
High NEEC       
 
Factors associated with high risk of metastasis, recurrence and decreased survival include deep 
myometrial invasion (50%) in combination with poor histological differentiation [99, 100].  
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Table 5. proportion of patients with positive lymph nodes in pelvis area (% from Annual 
Swedish rapport) 
Myometrial invasion Grade 1 Grade 2 Grade 3 
No invasion 1 7 16 
<50% 2 6 10 





The gold standard of surgical treatment is hysterectomy and bilateral salpingo-oophorectomy, 
which can be carried out either through laparotomy or by minimally invasive surgery, 
depending on staging. When disease is diagnosed at an early stage, minimally invasive surgery 
and laparotomy are equally effective [101]. 
 
1.9.2 Lymphadenectomy 
About 25% of EC patients demonstrate lymph node metastasis or lymphovascular space 
invasion (LVSI) [102]. Lymphadenectomy serves a therapeutic role and is also used for staging, 
though it should only be undertaken based on solid indications due to associated potential long-
term complications [103]. The 2015 consensus conference [1] concluded that at least ten lymph 
nodes should be removed and that the procedure should include pelvic and para-aortic 
lymphadenectomy. The critical anatomy stretches from the inferior mesenteric artery up to the 
renal vessels [1]. The importance of recognizing sentinel lymph nodes has become generally 
accepted practice internationally over the past few years, including in Sweden. The presence of 
a positive sentinel lymph node or lack thereof can impact patient survival or prevent 
unnecessary lymphadenectomy. The accuracy of sentinel nodes in predicting metastasis has 
been well demonstrated. As such, a small number of patients preoperatively assessed to be at 
low risk will nevertheless prove to have a positive sentinel node, while other patients assessed 
as being at high risk will occasionally be sentinel node-negative, and thereby able to avoid 
lymphadenectomy and its potential complications [104, 105]. There is approximately a 3% risk 






1.9.3 Adjuvant therapy 
Both risk group and risk assessment of recurrence determine whether adjuvant radiation 
therapy, chemotherapy, or a combination thereof is to be used. The choice is based on the 
classification system adopted at the 2016 ESMO-ESGO-ESTRO consensus conference [7]. The 
benefits of adjuvant therapy may include a positive impact on morbidity and improved overall 
survival among EC patients [107].  
1.9.3.1 Radiotherapy 
External beam radiation therapy (EBRT) benefits EC patients at intermediate risk through a 
reduction in risk of regional recurrence, though improved overall survival has not been 
demonstrated.  
 
The PROTEC-2 study compared the effects of EBRT with vaginal brachytherapy (VBT) on 
patients of high to intermediate risk and evaluated long-term outcomes. They concluded that 
VBT should be the standard of care to treat high-risk (HR) endometrial cancer, while EBRT 
should be standard treatment in patients with unfavorable risk factors such as the p53 mutation 
and LVSI [108].  
 
The currently ongoing PORTEC-4 trial is randomizing women with stage I-II EC and those 
otherwise at HR to be treated with either VBT or EBRT based on molecular profiling. Patients 
with unfavorable risk factors will be treated with ERBT, while those with favorable risk factors 
will receive VBT[108]. 
1.9.3.2 Chemotherapy 
Some randomized controlled trials have demonstrated benefit from the addition of 
chemotherapy to ERBT among HR patients [109]. Chemotherapy has proven beneficial for 
treatment of early-stage EC disease among patients with unfavorable risk factors, as well as for 
those in more advanced stages [109]. One meta-analysis that focused on progression-free 
survival (PFS) compared one group of patients receiving a combination of ERBT and 
chemotherapy with a second group that did not receive adjuvant chemotherapy and found 
improved PFS in the combination therapy group (78% vs 69%, respectively, in the two groups 
(p=0.009))[110]. However, combination therapy for late-stage disease was not associated with 





2 AIMS OF THE THESIS 
 
The overall aim of this thesis was to evaluate associations between a variety of risk factors – 
genetic and environmental – and endometrial cancer to ascertain how they influence 
prognosis, recurrence, and survival. 
The specific aims were: 
 
Study I  
To evaluate the prevalence of familial uterine cancer in Stockholm, Sweden. To explore the 
existence of hereditary uterine cancer related to Lynch syndrome or Cowden syndrome. To 
investigate the presence of a possible new cancer syndrome in patients with uterine cancer 
and a family history of other cancers. 
 
Study II 
This association study is designed to determine whether the TERT-CLPTM1L region is a 




To investigate expression of specific mitochondrial proteins such as the transcriptional 
coactivator Peroxisome proliferator-activated receptor gamma coactivator 1 (PGC1) and 
the Voltage-dependent anion channel type 1 (VDAC1) in endometrial cancer and to ascertain 
their association to prognosis, recurrence, and survival. 
 
Study IV 
To assess how dietary habits and physical activity affect prognosis, recurrence and survival 





3 PATIENTS AND METHODS 
3.1 SETTING  
The cohorts in our study originate from both retrospective and prospective data that were 
collected as part of an extensive project: RENDOCAS (Registry of Endometrial Cancer in 
Sweden). This study focuses on mapping heredity, identifying disease-causing genes in 
women with endometrial cancer, and developing early diagnostic markers for uterine cancer. 
We began collecting data in 2010 and invited women who had been diagnosed and surgically 
treated for endometrial cancer in Stockholm County, Sweden, beginning in 2008 to 
participate in the study and continued to invite women to participate prospectively with newly 
diagnosed endometrial cancer until March 2012. Participants (index patients) were asked to 
complete questionnaires addressing: 1) personal history of other cancer diseases, parity, 
comorbidity, medications, 2) family history of cancer, 3) dietary habits, physical activity, 
lifestyle (se supplementary). All participants had been treated with hysterectomy and bilateral 
salpingo-oophorectomy, with or without lymphadenectomy. Tumors were staged and graded 
according to FIGO 2009 staging Criteria [5]. Histopathological reports for all patients were 
verified through the medical records system. Diagnoses among family members were 
confirmed through the Swedish Cancer Registry. 
 
3.2. DATA SOURCE 
3.2.1 The Swedish cancer registry 
The Swedish cancer register was founded in 1958 and is managed by the National Board of 
Health and Welfare. Its fundamental aim is to register and monitor cancer incidence and 
survival. Healthcare providers are obligated to report each new case of diagnosed cancer to 
the relevant regional cancer center. The registry contains personal patient data, as well as 
medical data. Data may include personal identification number, sex, age, and demographic 






3.3 DEMOGRAPHIC DATA ON THE STUDY POPULATION 
 
Table 6. Study population 
Characteristics No/total (%) Median 
Range 
in ax 
Age at diagnosis, years   67   
Body mass index at diagnosis   26.3   
Hormone replacement 
therapy 
239/452 (52.9)   
Parity   2   
Diabetes mellitus 51/462 (11)   
Lipid lowering drugs 102/455 (22.4)   
Histology      
Endometrioid  394/481 (81.9)   
Serous or mixed 56/481 (11.6)    
Clear cell 9/481 (1.9)   
Sarcoma 20/481 (4.2)    
Hyperplasia with atypia 2/481 (0.4)   
Figo stage      
1A 316/480 (65.8)   
1B 95/480 (19.8)    
2 34/480 (7.1)   
3A 16/480 (3.3)    
3B 7/480 (1.5)   
3C 2/480 (0.4)    
4 3/480 (0.6)   
4B 7/480 (1.5)    
Grade     
1 193/480 (40.2)    
2 181/480 (37.7)   
3 106/480 (22.1)    
Depth of myometrial invasion     
None 64/481 (13.3)    
<50% 282/481 (58.6)   
 128/481 (26.6)    
Through the serosa 7/481 (1.5)   






 Study I 
The study included 481 patients with confirmed diagnosis of EC who underwent 
hysterectomy and bilateral oophorectomy, with or without lymphadenectomy. Of the 890 
patients invited to participate, 481 (54%) agreed. All participants provided written informed 
consent and had a blood sample drawn for DNA analysis, in line with standard procedure at 
the Department of Clinical Genetics, Karolinska University Hospital. Histopathological 
analysis of the uterine cancer was recorded for each patient. In addition, participants 
completed a questionnaire that included data on personal and family history of cancer. 
 
Study II 
A collaborative effort known as the Endometrial Cancer Association Consortium (ECAC) 
enrolled 5591 women of European ancestry with a histologically confirmed diagnosis of 
endometrial cancer. The studies conducted in 11 separate centers in Western Europe, North 
America and Australia. A total of 28 984 healthy women of European ancestry and known 
age at time of sampling were chosen from studies in the above countries to serve as a control 
group. 
The Swedish contribution to this multicenter study is represented by the Registry of 
Endometrial Cancer in Sweden (RENDOCAS), a hospital-based register of consecutively 
occurring EC cases. As part of the ECAC effort, our study enrolled 262 EC patients who had 
undergone surgical treatment at Karolinska University Hospital, Solna, Sweden, between 
2008 and 2011. The following material and data were collected for each patient: DNA sample 
isolate from peripheral blood, histopathological analysis of the tumor, and detailed family 
history. Participants also completed a questionnaire focused on additional factors known to 
be associated with EC, including BMI, DM, HRT, and parity. 
 
Study III 
For study III, a cohort of 148 patients were selected from the previous group.  Of these cases, 
126 (85%) represented EC type I and 22 (15%) EC type II. Upon hysterectomy, tissue 
samples, about 1 cm square, were obtained from both the tumor and adjacent macroscopically 







Study IV enrolled the 481 patients from study I who completed a questionnaire on topics 
related to activities of daily life, dietary habits, alcohol consumption, and smoking, after 
which these data were subjected to machine learning. 
 
3.5 METHODS 
Study I  
All participants were contacted for a telephone interview for the purpose of constructing a 
pedigree, based on questionnaire information and interview confirmation. All pedigrees 
included information concerning first-degree relatives (FDRs), second-degree relatives, and 
first cousins. Current age or age at death, type of cancer, and age at diagnosis were recorded 
for all relatives with cancer. Most cancer diagnoses among relatives were histologically 
verified through the Swedish Cancer Registry, medical records, and/or death certificates with 
written consent from the patient or, if deceased, from the closest living relative.  
 
All pedigrees were analyzed for the possible presence of a potentially hereditary endometrial 
cancer syndrome. Participants meeting the Amsterdam II criteria for Lynch syndrome or the 
National Comprehensive Cancer Network (NCCN) testing criteria v1. 2009 [113] for 
Cowden syndrome, and who were therefore at risk for either of these syndromes were thereby 
identified. These patients were offered genetic counseling at the Department of Clinical 
Genetics, and mutation screening for causative genes was carried out according to standard 
procedure. These patients were informed about surveillance programs and advised about 
further investigation of family members.  
 
All pedigrees were evaluated for cancer in close relatives, with a special focus on putative 
hereditary uterine cancer and colorectal, breast, and ovarian cancer. Relative frequencies of 
different cancers were compared with those in Sweden's general cancer population in 1970 
and 2010. Families with at least two cases of uterine cancer (including the index patient) were 
compared with families having only one case in order to identify possible cancer syndrome 
characteristics. The International Classification of Diseases Revision 7 (ICD-7) was used to 








The Collaborative Oncological Gene–environment Study (COGS), involving a method 
known as Illumina iSelect high-density genotyping array (iCOGS Genotyping array) with 
211 155 SNPs, was used for this study to analyze germline DNA extracted from blood. This 
study selected 113 genotyped and 283 imputed SNPs (total 396 SNPs) from a 200kb region 




Study III included all patients from whom paired tissue samples were obtained (benign and 
malignant). Histological records were obtained from the pathology reports in the medical 
records system, including information such as: histological type of tumor, tumor 
characterization according to the International Federation of Gynecology and Obstetrics 
(FIGO) staging system, histological grade, and myometrial invasion. Evaluation concerning 
hormone receptor status, p56, and ploidy were conducted at the Karolinska Hospital 
pathology laboratory.  
 
All paired samples were formalin-fixed on paraffin-embedded tumor blocks, sliced into 4 
µm-thick sections and subjected to routine immunohistochemistry staining using the 
Vectastain Elite ABC kit. The slide sections were incubated with the primary antibodies Anti-
Ki-67 and anti-PGC1α for 30 minutes at room temperature and subsequently with the 
secondary antibody (horse anti-rabbit (BA-1000) or horse anti-mouse (BA-2000), both 
Vector Laboratories), before adding the avidin-biotinylated peroxidase complex. The stained 
results were evaluated by blinded observation. All slides were independently evaluated by 
assessment of the entire tumor area (malignant) and of the epithelial cells in control tissues 
(benign).  
 
Evaluation of immunohistochemistry.  All slides were individually evaluated by 
two observers who were blinded as to clinical outcome. The evaluation encompassed both 
epithelial cells in healthy tissue and cancerous cells in tumor tissue. Samples were observed 
for positive PGC1α and VDAC1 immunoreactivities and measured for percent of positively 
stained cells. The scoring system described above was used to semi-quantitatively categorize 
positively stained cells on a scale of 0 to 3 (0 <1%; 1 - 1-25%; 2 – 25-50%; 3 - >50%); the 
same scoring system was used to determine staining intensity 0-3 (0-negative; 1 – weak; 2 – 
Moderate; 3 – Strong). The immunoreactivity score is the result of these two parameters 
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(scoring systems) considered together. The tumor (T) and normal (N) tissue, T/N 
immunoreactivity was trichotomized as T/N<1, T/N = 1, or T/N >1. 
 
Study IV 
All participants in the study were given two questionnaires for completion. The 
questionnaires addressed topics relating to activities of daily life, dietary habits, alcohol 
consumption, and smoking. In addition, comorbidities, medications, parity, and hormonal 
therapy were also addressed. Following processing and data extraction, the relevant variables 
were grouped into different categories.  Medical records were reviewed from which clinical 
data were extracted, including histopathological data concerning tumor characterization, 
follow-up for recurrence, and survival. Figure 7 includes a sampling from the total of nearly 
180 variables.  
 






3.6 STATISTICAL ANALYSIS 
Chi-square test: The chi-square test is used to assess data that follow a nominal scale or 
ordinal scale and tests the differences in binary outcomes between two or more independent 
groups. 
 
Monte Carlo simulation: Monte-Carlo significance test procedures [114]  compare the 
observed data with random samples generated by following the hypothesis being tested. 
 
Wilcoxon signed-rank test:  a nonparametric test that can be used to determine whether two 
dependent samples were selected from populations having the same distribution. Two 
samples can be compared to assess whether their population means ranks differ. It provides 
an alternative to the t-test when the distribution of the difference between means of two 
samples cannot be assumed to be normally distributed. 
 
Admixture maximum likelihood (AML) method: This is a method developed to analyze 
multiple, common variants for association with a specific trait. It is an approach that 
developed in order to estimate  both the proportion of associated SNPs and their size of effect 
[115]. 
 
Bayesian: Bayesian has different models but it’s a mathematical procedure applied to update 
the probability for a hypothesis. It can be used to confirm AML result. 
 
Kaplan-Meier analysis: The Kaplan-Meier provides a graphical means for illustrating 
survival or time-to-event analysis. The Kaplan-Meier curve shows the probability that a 
specific event will occur within a defined time interval. The horizontal axis represents the 
time from enrollment corresponding to the time at which participants are considered to be at-
risk for the outcome of interest, while the vertical axis represents the estimated probability 
of survival or possible other outcomes. Each downward step in the lines represents an event 
(outcome), and each small vertical tick represents a censored observation. Censoring means 
that the total survival time for that subject cannot be accurately determined, which occurs 
when an individual drops out of the study, is lost to follow-up, or the study ends before the 
subject experiences the event of interest; over time, fewer people remain at risk. Survival 




Spearman´s rank: Spearman's correlation coefficient measures the strength and direction of 
association between two ranked variables. 
 
Kruskal-Wallis H test: is a rank-based nonparametric test used to determine whether 
statistically significant differences occur between two or more groups of an independent 
variable on a continuous or ordinal dependent variable. 
 
Mann-Whitney U test: The Mann-Whitney U test is used to compare differences between 
two independent groups when the dependent variable is either ordinal or continuous, but not 
normally distributed. 
 
Cox regression: Also known as proportional hazards regression,  is used to investigate the 
relationship of predictors and the time to the event through a hazard function. Cox regression 
is time-dependent and provides an estimate of the hazard ratio (HR), which reflects the 
relative risk of an event occurring over a given timeframe, or the relative event rate. It 
provides an assessment of rate, referring to number of new cases of an outcome per 
population at risk per unit of time. An HR>1 means that the event is more likely to occur, 
while HR<1 means that the predictor is likely to have a protective effect. When HR equals 
1, the predictor likely does not influence the hazard of the event.  
 
Logistic regression: It is used to predict the probability of a certain prognosis or investigate 
the relationship between different variables and outcome. We can obtain odds ratio (OR)  Its 
used when the dependent variable is categorical. The OR is the impact of the variables 
independently, meaning it helps overcome confounders.  Conditional logistic regression is 
commonly used for case-control data in order to match data. Unconditional logistic 
regression is  used when the data is not matching, than one can compare conditional to 
unconditional results. 
 
Random Survival Forest: The Random Survival Forest (RSF) is an extension of the Random 
Forest model, introduced by Breiman in 2011. RSF is an attractive alternative approach to 
the Cox proportional hazards (PH) models since PH could be restricted by the assumption 
that proportional hazards are violated. Survival tree methods are fully non-parametric, 
flexible, and can easily handle high-dimensional covariate data. RSF processes the data and 
builds a model capable of further analyzing the variables in order to evaluate how informative 
a specific variable actually is, referred to as Variable Importance (VIMP). VIMP assesses the 
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change in prediction accuracy should a particular variable be excluded from the model; the 
highest-ranked variables decrease prediction power the most. Minimal depth evaluates the 
variables in terms of how close they split nodes nearest to the root node. Since VIMP and 
minimal depth are calculated differently, we ranked our variables using both. 
 
Study I 
Using the Swedish Cancer Registry to obtain data for a reference population, our study 
assessed the relative rates of cancers diagnosed in the family members of our index patients 
and compared them with those of the cancer population in Sweden. From the latter, we 
limited our data collection to 1970 and 2010 to be used as a basis for comparison with our 
material so as to compensate for any differences in incidence over time. We used binomial 
distribution to calculate 95% confidence intervals (CIs). We converted site-specific CIs from 
numbers to proportions by dividing the number of cancers among family members at a 
specific site by the total number of cancers among these family members. Chi-square tests 
were run on tables containing categorical data to check for heterogeneity. P-values were then 
calculated by using Monte Carlo simulation in the chi-square tests. Shifts in distribution 




Initially we employed the admixture maximum likelihood (ADM) test to examine the 
association between EC and various SNPs. This global test was run against the null 
hypothesis that none of the genotyped SNPs within the region are associated with endometrial 
cancer. We used unconditional logistic regression, with a per-allele (1df) model, that was 
based on expected genotype dosages for imputed SNPs to obtain an estimate of associations 
among various SNPs and EC. To ascertain independently associated SNPs, we then applied 
forward and backward stepwise logistic regression. Secondary analysis was undertaken in 
regard to the most significant independent SNPs to test for specific associations with 
endometrioid and non-endometrioid EC. The samples derived from iCOGS were used as a 
basis to calculate pairwise linkage disequilibrium measures. In addition, we subjected all 
genotyped and imputed SNPs in the region to simultaneous analysis using the Bayesian–
inspired penalized maximum likelihood approach in order to identify the optimal subset for 






The Wilcoxon signed-rank test was used to compare expression of PGC1α and VDAC 1 in 
the malignant and benign paired tissue samples. The cohort was stratified according to the 
Wilcoxon test so as to compare expression of PGC1α at different stages. The Kaplan-Meier 
and log-rank test was used to assess survival as correlated with expression of PGC1α and 
VDAC1, while the Spearman’s rank test was used to investigate the correlation between 
tumor characteristics and each of the genes PGC1α, TFAM, and p53, respectively. Since this 
study primarily dealt with non-normally distributed data, we used the Mann-Whitney U when 




The Mann-Whitney U test was used to compare continuous variables between unpaired 
samples, while, because of the non-normal distribution of continuous variables, the χ2 test 
was used for categorical variables. Next, the Cox proportional hazards model was used to 
evaluate the association between survival or relapse time and various predictor values. P-
value was set at 0.05. Due to the many variables involved, as well as the attendant risk for 
multicollinearity, which may result from multiple testing, we applied Random Survival 
Forest (RSF), an extension of Breiman’s learning method, for right-censored data [116]. RSF 
was used to analyze time to event, which was either death or relapse. The ForestSRC [117] 
and the ggRandomForest packages [118] were used to visualize the data. The function of 
RSF is to process the variables and construct a model in which two primary measurements 
are evaluated to determine how informative each separate variable actually is, referred to as 
Variable Importance (VIMP) and minimal depth.  
 
The Random Forest SRC package handles the missing values by imputing them through 
adaptive tree imputation. Notably, exploratory data analysis shows that most features in our 
study had fewer than 1% missing data points. 
 
 
Study I analyses were performed using R(R core team 2012), study III using IBM SPSS 25.0, 









Table 7. Overview of studies I-IV 
KS – Karolinska University Hospital, ECAC - Endometrial Cancer Association Consortium, IHC – 




Variables Study I Study II  Study III Study IV 
Type of study Cohort 
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3.7 ETHICAL CONSIDERATION 
The 1964 Declaration of Helsinki addresses medical research principles where human 
material and data are involved. One of the key important statements is as follows: “It is the 
duty of physicians who are involved in medical research to protect the life, health, dignity, 
integrity, right to self-determination, privacy, and confidentiality of personal information of 
research subjects. The responsibility for the protection of research subjects must always rest 
with the physician or other health care professionals and never with the research subjects, 
even though they have given consent.” [119]. 
The principles outlined in the Declaration aim to protect personal integrity in the processing 
of personal data. More recently, pursuant to the Swedish Personal Data Act, research can 
only be conducted in Sweden if ethical permission is granted by one of the six ethical boards. 
 
Ethical perspectives  
The studies are based on data collected from patients who provided consent to participate in 
the study. Data were obtained from medical records, including histopathological analyses of 
tissue samples. The tumor slides in study III were not sectioned for IHC staining until after 
completion of clinical pathological analyses.  Patients completed questionnaires concerning 
lifestyle, environmental factors, and family history. Blood sampling was undertaken, a simple 
procedure with few attendant and mild risks, such as local hematoma or at worst, phlebitis.  
Our genetic studies (study I) posed an interesting ethical dilemma regarding both index 
patients and their family members. Though study patients provided consent to participate in 
this study, which included genetic testing, they may not have been entirely aware of the 
potential consequences of being diagnosed with a genetic disorder entailing increased risk of 
other (non-endometrial) cancers, which could result in attendant worry and concern with a 
negative impact on quality of life and mental health. However, in  most cases such concerns 
may be mitigated by the ability of the Department of Clinical Genetics to offer enrollment in 
surveillance programs aimed at early detection of tumors in the specific organs at risk. A 
second dilemma concerns the relatives of our study patients, since they did not provide 
consent to participate in the study. Should a hereditary cancer syndrome be discovered, they 
would be contacted by the index patient and informed of their potential increase of risk for 
cancer, in which case they too can be offered carrier testing and, if necessary, be included in 
preventive screening programs. Situations may arise in which the index patient refuses to 
contact relatives. As researchers, we would be left with the knowledge that these family 
members may be at increased risk for developing a preventable cancer illness that could be 
diagnosed at an early stage, but would be unable to use that information to directly contact 
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at-risk individuals. This would not be an uncommon dilemma when investigating families at 
the Department of Clinical Genetics, which has extensive experience of such issues. 
 
Studies II-IV concern patients who are not thought to be either positively or negatively 
impacted.  However, these studies could potentially improve the prognosis of women 
diagnosed with endometrial cancer in the future by identifying molecular markers or dietary 
risk factors that could contribute to early diagnosis and improved treatment strategies for 
individual patients. 
 
Ethical approval for studies I-IV: The regional ethical committee at Karolinska Institutet, 
Stockholm, Sweden, approved the study protocol (DNR 2010/1536-31/2), dates of approval 
November 1st 2010. 
Ethical approval for study II: QIMR Berghofer-HREC – P1051 
Ethical approval for study III and IV: The regional ethical committee at Karolinska 
Institutet, Stockholm, Sweden approved the study protocol (No. 2006/649-31/4), dates of 
approval June 20th 2006. 
 
Funding: This thesis, with its included studies, was funded through grants from the Swedish 
Research Council and the Stockholm County Council's grants. The funding sources had no 
role in study design, collection of data, analysis or interpretation of data, nor in the decision 





4.1 STUDY I 
Among relatives of our index patients, we uncovered 1316 diagnoses of cancer, 73 (6%) of 
which were endometrial cancer. When comparing these findings with the figures from the 
general population in 1970 and 2010, we found the proportion of EC among our study 
population to be relatively higher than among the general population in these two 
comparative years (4% and 3%, respectively). Overexpression of EC also occurred at a higher 
rate among first-degree relatives, with or without second-degree relatives, in relation to the 
general population. Family members of index patients also demonstrated overrepresentation 
of stomach/unspecified abdominal cancer as well as laryngeal cancer.  
In contrast, the relatives of index patients did not demonstrate overrepresentation of breast 
cancer (16%), colon (8%), rectal (3%), and ovarian (25).  In fact, such family members 
showed a lower occurrence of cancers of the pancreas, rectum, urinary tract, 
lip/tongue/mouth, endocrine glands (excluding thyroid), peritoneum, pharynx, small 
intestine, eye, mediastinum, nose, as well as non-Hodgkin’s lymphoma and myelofibrosis. 
 
Presence of hereditary cancer syndromes 
In order to explore possible hereditary cancer syndromes such as LS, we constructed 
pedigrees for our index patients, 9 (2%) of whom fulfilled the Amsterdam II criteria. Median 
age of those patients was 58 (range 39-80). Of these, 7/9 were found to have a deleterious 
mutation in mismatch repair genes, while 4 had a mutation in MSH2 (c.1147C> T; 
c.1786_1788del; deletion of exon 7-10 and deletion from exon 3 of the EPCAM gene to exon 
6 of MSH2) and 3 patients had a mutation in MLH1(c.546-2A> G; c.790+1G>c and deletion 
of exon 1-3). One patient among these 7 came from a known LS family.  We found no MSH6 
mutations in any patient and none of the index patients fulfilled the NCCN criteria for 
Cowden syndrome.  
 
To summarize, our study revealed LS in 6 of the study families, see Figure 8. Assessment of 
pedigrees resulted in 9 families that fulfilled the Hereditary Breast and Ovarian Cancer 
(HBOC) criteria. However, because the index patients declined screening, three families did 
not undergo mutation screening, while six families were screened for BRCA 1 and BRCA 2 






Figure 8. Pedigrees of two LS families conducted during our study 
 
Family history of cancer 
At least 59% of our index patients reported a family history of cancer with at least one relative 
having this diagnosis, while 24% had at least two relatives.  
When exploring the link between EC and ovarian, breast, and colorectal cancer, we found 
that 17% of our index patients were shown to have family members with breast cancer, 12% 
with colorectal, and 6% ovarian cancer.  
Table 8 presents the distribution of cancer among relatives of index patients. 
 
Table 8. Family history of cancer among 481 index cases 
Heredity No                  % 
At least 3 first-degree-relatives with any cancer 38 8 
At least 2 first-degree-relatives with any cancer 113 24 
At least 1 first-degree-relatives with any cancer 285 59 
At least 1 first-degree-relatives with any cancer OR 
82 17 
At least 2 relatives* with breast cancer 
At least 1 relative* with endometrial cancer 64 13 
At least 1 first-degree-relatives with endometrial 
cancer 
33 7 
At least 1 first-degree-relatives with colorectal cancer 
OR 
57 12 
At least 2 relatives* with colorectal cancer 
At least 1 relative* with ovarian cancer 29 6 
At least 1 relative* with any cancer diagnosed at <50 
years old 




When assessing the association between EC among our index patients and their relatives with 
EC, we found that 64 patients (13%) had at least one relative with EC. We found no 
differences in patient characteristic among these 64 patients compared with the other 417 
index patients who had no relatives diagnosed with EC, with the exception of statistical 
significance in the number of patients diagnosed with EC before age 50 in the first group 
(p<0.001). Table 9. Two LS families were found among those patients. 
 
Table 9. Comparison of the characteristics and variables in families with and without 
relatives with endometrial cancer 
    
Uterine cancer in family 
n= 64 
No Uterine cancer in 
  
family n= 417 
    Median Range Median Range P-value 
Age(years)   65 (36,87) 67 (34,95) 0.082* 
Body mass 
index 
  26.6 (17.6,43.4) 26.2 (17.7, 55.1) 0.466* 
    No Row % No Row %   




4 6 52 12   
  Clear cell 3 5 6 1   
  Sarcoma 5 8 15 4   
  Hyperplasia 0 0 2 0   
Figo stage 1A 45 70 271 65 0.367** 
  1B 11 17 84 20   
  2 2 3 32 8   
  3A 4 6 12 3   
  3B 0 0 7 2   
  3C 0 0 2 0   
  4 0 0 3 1   
  4B 2 3 5 1   
Relapse No 61 95 403 97 0.726** 
  Yes 3 5 14 3   
Ploidy Aneuploidy 13 22 108 28 0.338** 
  Diploid 47 78 274 72   
Multiple 
cancers 
No 52 81 354 85 0.478** 
  yes 12 19 63 15   
Uterine 
cancer <50 
years of age 
No 57 89 389 93 0.300** 
  Yes 7 11 28 7   
Relatives 
with cancer 
<50 years of 
age 
No 34 53 310 74 0.001** 
  Yes 30 7 107 26   
* Wilcoxon rank sum test. ** Chi.sq test 
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Presence of multiple cancer in index patients 
When evaluating our index patients for multiple cancers, we found 75 (16%) with at least 
one additional cancer, 9 of whom had 3 different cancer diagnoses. 
Breast cancer - In all, 34 were diagnosed with breast cancer, 31 of whom were identified 
prior to being diagnosed with EC; only 2 were diagnosed with EC first, and 2 others were 
diagnosed at the same time. The median time interval between these two diagnoses in the 
former group was 7 years. Only 12 index patients were treated with selective estrogen 
receptor modulators as part of their breast cancer treatment regimen. Histological findings 
among patients treated with Tamoxifen did not differ from those of the study population. 
While 7 of the patients with breast cancer also had an additional cancer diagnosis, including 
colorectal, myeloma, skin cancer, salivary gland, and malignant melanoma, no pattern of 
significance was found. 
Colorectal cancer - In all, 14 patients had an additional diagnosis of colorectal cancer, 12 of 
whom were diagnosed prior to EC, 1 at the same time, and one afterwards. The median time 
interval between these cancer diagnoses was 6 years. In addition, 2 of the 14 patients were 
also diagnosed with urinary tract or skin cancer. 
Ovarian cancer – In 4 index patients, the diagnosis was made simultaneously.  
 
Moreover, 4 of our index patients with multiple cancer diagnoses also had Lynch syndrome. 
 
Table 10. Multiple tumours in 75 of 481index cases 
CRC – Colorectal cancer, BC – Breast cancer 
112/34 Had therapy with selective estrogen receptor modulator   
211skin cancer, 4 lymphoma, 4 cervix cancer, 5 malignant melanoma, 2 Urinary tract, 2 myeloma, 1 Kidney, 1 CNS, 1 
















Breast  34/75 (45%)1 34/481 (7%) 7/34 
CRC+myeloma, CRC+skin, CRC(nr 2) 
salivary gland, malignant melanoma, skin 
Colorectal  14/75( 19%) 14/481 (3%) 6/14 
BC+myeloma, BC+skin, BC (nr 2), urinary 
tract, skin 
Ovarian  4/75 (5%) 4/481 (0.4%) 0/4   
Other2 34/75 (45%) 34/481 (7%) 7/34 
Skin (nr 3), myeloma, salivary gland, 
malignant melanoma, urinary tract 
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4.2 STUDY II 
SNP data related to the 5p15 region were generated for 4401 cases and 28 758 controls. Using 
the costume-designed Illumina iSelsect (iCOGS) array we genotyped our samples. The 
iCOGS includes 118 genotyped SNPs. We then imputed the additional genotypes using 1000 
Genome project data as a reference.  
When performing an admixture maximum likelihood (AML) test against the null hypothesis 
claiming that none of the genotyped SNPs within the TERT –CLPTM1L region are associated 
with EC, significant evidence was obtained that at least one SNP is associated (P = 0.0001) 
with EC. A total of 61 SNPs out of 396 (113 genotypes + 283 imputed) that generated P 
values <0.05 (as compared with <20 expected by chance) were able to be identified through 
single-SNP association testing.  
Using forward stepwise logistic regression, additional testing uncovered three imputed SNPs 
(rs7705526 (in SNP set 1, set of 12 SNPs), rs13174814 (SNP set 2, set of 4 SNPs) and 
rs62329728 (SNP set 3, set of 10 SNPs)) each of which was backed by evidence of 
independent association with EC with a respective OR of 1.11, 0.87, and 1.27 based on 
unconditional analysis (table 11). Further support that these SNPs represent independent risk 
factors for EC comes from the weak linkage disequilibrium (LD) between them. rs7705526 
is located in an LD region that has previously been found to be associated with other cancers, 
including ovarian and breast, where it can be found in the first intron of TERT. All SNPs 
were subjected to a Bayesian-inspired penalized maximum likelihood approach in order to 
define the optimal subset that can be used to predict disease, a step that further supports the 
evidence that SNP set 1 and 2 play a role in EC.  
 
Finally, data obtained from the cancer genome atlas (TCGA) found increased expression of 
both TERT and CLPTM1L RNA in EC tissue compared with normal tissue. 
 









Uncondonditional  analysis Conditional analysis 
 
 
     OR (95% CI) P value OR (95% CI) P value 
Rs7705226 1,285,974 C/A 0.33 0.89 1.11 (1.06, 1.17) 7.7E-05 1.08 (1.02, 1.14) 9.7E-03 
Rs13174814 1,299,859 G/C 0.25 0.98 0.87 (0.82, 0.93) 4.9E-06 0.89 (0.84, 0.95) 1.7E-04 
Rs6239728 1,356,890 G/A 0.06 0.82 1.27 (1.14, 1.43) 2.2E-05 1.24 (1.11, 1.39) 1.8E-04 
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4.3 STUDY III 
We used immunohistochemistry to study expression of PGC1α and VDAC1 among EC 
patients with a median age of 70.0 (Range 65.2-77.0) at time of diagnosis. Of these, hormone 
replacement therapy had previously been prescribed to 67 of the total of 146 (44.9%) patients. 
Median BMI was 26.3 (23.7-30.1) and parity - 2 (1-3). Table 12 presents tumor 
characteristics. 
 
Table 12. Tumour characteristics (n=148)  
Characteristics No (%) 
Histology   
   Endometroid 125 (84.5) 
   Serous or mixed 15 (10.1) 
   Clear cell 7 (4.7) 
Stage   
       1 103 (69.6) 
       2 25 (16.9) 
       3 17 (11.1) 
       4 3 (2.0) 
Grade   
       1 39 (26.4) 
       2 60 (40.5) 
       3 49 (33.1) 
Depth of myometrial invasion   
   None 10 (6.8) 
   <50% 72 (49.0) 
   50%     63 (42.9) 
   Through the serosa 2 (1.4) 
Relapse 25 (16.9) 
 
 
The subtypes demonstrated the expected distribution of hormone biomarkers. There was a 
20-fold higher percentage of Ki67 positive cells in malignant tissue than in benign tissue. A 
significant correlation was observed between Ki 67 expression and shorter time to relapse 
(p<0.001) (Figure 9) 
 
PGC1α expression in EC: PGC1α expression was found to be decreased in malignant tissue 







Figure 9. Ki-67 expression. The Ki-67 index, or percentage of tumour cells with a positive nucleus in 
immunohistochemistry was significantly higher in tumour cells 31.1 (14.6, 47.9) vs 1.00 (0.38, 2.60), 
P<0.0001;Wilcoxon signed rank test*P<0.05 
 
 
Figure 10. PGC1 expression. Immunohistochemical staining and scoring for PGC1 demonstrated     
significantly lower expression in tumour than in benign tissue 3.0 (3.0, 6.0) vs.9.00(6.00, 9.00); P<0.0001; 
Wilcoxon signed rank test. Expression levels (y-axis) are based on the proportion of positive cells and the 
intensity of staining. PGC1, peroxisome proliferator activated receptor  coactivator 1.  
 
 
The Mann-Whitney U test uncovered no association between PGC1α expression and tumor 
subtype (p=0.113;), nor was any association found between PGC1α expression and invasion, 
stage, or tumor grade (Table 13). No significant correlation was demonstrated between 
PGC1α expression and tumor size, nor was any association found between PGC1α expression 
and relapse or mortality (p=0.345 and 0.758 respectively; Log-rank test). 
Perhaps somewhat surprisingly, the lower PGC1α expression observed in stage I FIGO 




Table 13. Tumour characteristics 
Characteristics No PGC1 score, median (IQR 25,75) p-value 
Invasion       
0 9 4.00 (3.00, 6.00) 0.294 
1 73 4.00 (3.00, 6.00)   
2-3 65 3.00 (3.00, 6.00)   
Stage       
1 103 3.00 (3.00, 6.00) 0.773 
2 25 6.00 (3.00, 6.00)   
3-4 20 6.00 (3.00, 6.00)   
Grade       
1 39 3.00 (3.00, 6.00) 0.903 
2 60 3.50 (3.00, 6.00)   
3 49 6.00 (3.00, 6.00)   
Tumor size*(mm)       
30 47 3.50 (3.00, 6.00) 0.090 
 >30 43 3.00 (3.00, 6.00)   
Histology       
Type I 125 3.00 (3.00, 6.00) 0.113 
Type II 22 6.00 (3.00, 6.00)   
 
*Data from the 90/148 sample which size was documented. PGC1 expression is shown as a semiquantitative score based 
on the categorization of percentage of positively stained cells and the maximum staining intensity. The Kruskal-Wallis test 
was used for comparing several groups, and the Mann-Whitney U test for comparing two groups.  
 
 
TFAM - Analysis of this mitochondrial transcription factor TFAM showed a significant 
decrease in expression in malignant tissue (p=0.016). 
 
VDAC1 – VDAC1 expression was significantly lower in tumor tissue than in benign tissue 
(Fig 11). Intermediate VDAC1 expression also weakly correlated with shorter time to relapse 
(P=0.03, Chi26.81; Log-rank test)(Fig.12), though the correlation became non-significant 






Figure 11. VDAC1 expression. Immunohistochemical staining and scoring for VDAC1 demonstrated 
significantly lower expression in tumour tissues than in benign tissue 6.0 (6.0, 9.0) vs. 9.00(6.00, 9.00); 
P=0.005; Wilcoxon signed ranked test Expression scores (y-axis) are based on the proportion of positive cells 






Figure 12. A weak correlation of VDAC1 expression and shorter time to relapse was observed. P=0.03, 





4.4. STUDY IV 
In all, 890 questionnaires were sent, of which 481 were completed and returned (drop-out 
rate 46%). Median patient age was 67.00 years [IQR 61.75 - 75.00], BMI - 26.50 [IQR 23.47 
- 30.45]. Table 14 summarizes patient characteristics. 
Table 14.  Background clinical and tumours characteristics of the study group 
Background characteristics                                                              No (%) 
Education 
< High school 152 (36.5) 
High school 108 (26.0) 
> High school 139 (33.4) 
Diabetes 
Yes 46 (11.1) 
No 369 (88.7) 
Ever use of lipid-lowering therapy 
Yes 92 (22.1) 
No 320 (76.9) 
Ever use of hormone replacement therapy 
Yes 208 (50.0) 
No 203 (48.8) 
Smoking 
Yes 181 (43.5) 
No 204 (49.0) 
Tumor characteristics 
Stage 
IA 279 (67.1) 
IB 80 (19.2) 
II 29 (7.0) 
IIIA 13 (3.1) 
IIIB 8 (1.9) 
IVA 1 (0.2) 
IVB 6 (1.4) 
Type  
Endometrioid adenocarcinoma 382 (91.8) 
Serous carcinoma  25 (6.0) 
Clear cell carcinoma 9 (2.2) 
Grade  
G3 82 (19.7) 
G2 151 (36.3) 
 G1 183 (44.0) 
Ploidy 
Aneuploid 111 (27.3) 





Our most recent follow-up was on February 1, 2019 when 54 women were found to have 
experienced relapse of EC (13.0 %), with a 20-month median time-to-relapse [IQR 12,75-
29,00]. As expected, relapse and decreased overall survival were associated with advanced 






Figure 13. Comparison of the age distribution between women who had a relapse or died and those who did 
not (p=0.02 and p<0.0001 respectively).   
Median is marked with white dot, while interquartile range - with black bars around 
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Table 15. Relapse and survival between patients with different tumor characteristics 
  
Relapse  Death 
No (%) No (%) 
Stage** 
   IA 17 (6.09%) 36 (12.90%) 
   IB 20 (25.00%) 23 (28.75%) 
   II 5 (17.24%) 8 (27.59%) 
   IIIA 8 (61.54%) 8 (61.54%) 
   IIIB 1 (12.50%) 4 (50.00%) 
   IVA 1 (100%) 1 (100%) 
   IVB 2 (33.33%) 3 (50.00%) 
Type of EC* 
   Endometrioid  43 (11.26%) 67 (17.54%) 
   Serous carcinoma 7 (28.00%) 10 (40.00%) 
   Clear cell carcinoma 4 (44.44%) 6 (66.67%) 
Grade of EC* 
   G1 14 (7.65%) 27 (14.75%) 
   G2 21 (13.91%) 30 (19.87%) 
   G3 19 (23.17%) 26 (31.71%) 
Ploidy** 
   Diploid 25 (8.47%) 44 (14.92%) 
   Aneuploid 26 (23.42%) 36 (32.43%) 
*p < 0.05; **p < 0.0001 (According to χ2 test) 
 
In this group, mean OS was 45 months [IQR 29.00-74.00] and a total of 83 patients died 
(20.0%). 
The study continues by applying the progression-free survival (PFS) model to analyze all 
variables as predictors. Relapse and death from any cause were designated as the main events, 
while OS and time-to-relapse were designated as the time-to-event characteristics. Note that 
when PFS was considered in relation to relapse, both death and OS period were excluded 
(and vice versa), in order to avoid misrepresenting these significant variables. Next, VIMP 
and minimal depth were calculated for all variables and sorted in descending order. Table 16 











Table 16. Features sorted in descending order of importance based on VIMP and minimal 
depth assessments 
                          Death                            Relapse 
VIMP  Minimal depth VIMP Minimal depth 
Stage Age at diagnosis Stage Stage 
Age at diagnosis Stage Ploidy Fried potatoes 





Other soft drinks soda  Other soft drinks soda  Skin reaction Tumor type 
Prunes Liver pate  Fried potatoes Other soft drinks soda  
Other fruit Coffee unfiltered  Differentiation Fruit yoghurt sour milk  
Age discontinued 
(alcohol) 
Fried potatoes Tumor type Beetroots 
Differentiation Ploidy Meat toppings Age at diagnosis 
Physical activity Physical activity Sun behavior Liver pate  
 
Certain variables rank highly both according to VIMP and minimal depth. The focus was 
mainly on relapse and death as the main events. Variable features in order of importance for 
relapse include: stage, ploidy, tumor type, prunes, and fried potatoes. Variable features in 
order of importance for death include: age, stage, tumor type, ploidy, other carbonated soft 
drinks final, physical activity, and age at which alcohol consumption was discontinued. Age 
and tumor characteristics are well-known modifiers of PFS and OS in EC and these were 
taken into account in the exploratory data analysis of our study. For this reason, we would 
also like to turn our attention to other variable features, such as dietary habits, alcohol 
consumption and physical activity. 
Concerning this group of variables, we ran the Cox proportional hazard models; Table 16 
presents the analysis of the patterns obtained. To summarize, fried potatoes increased the risk 
of EC, while Prunes had no impact on risk of EC relapse or death. Even after adjustment for 
BMI, age, and smoking status, the hazard remained. Similarly, carbonated soft drinks 
increased risk of death [HR=3.262; CI 95%, 1.834-5.800] and likewise, the hazard remained 
after adjustment for confounders.  
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In contrast, physical activity had an inverse impact on these risks. A 7.3% reduction [CI 95%, 
0.892-0.964] was associated with each incremental unit of Metabolic Equivalent (MET/day) 
of physical activity. The positive impact of physical activity persisted even after adjustment 
for age and BMI, but not for tumor stage (Table 17).  
 
Table 17. Hazard ratios of developing EC relapse or death according to specific dietary 
factors and physical activity 
               Unadjusted            Adjusted  
Covariate   HR (95% CI) P-value HR (95% CI) P-value 
Fried 
potatoes 
death 8.624 (2.217-33.555) 0.002 4.442 (1.094-18.040) * 0.037 




death 3.262 (1.834-5.800) < 0.0001 2.127 (1.169-3.867) * 0.013 
relapse 2.243 (0.983-5.119) 0.055 1.563 (0.751-3.255) * 0.233 
Physical 
activity  
death 0.927 (0.892-0.964) < 0.0001 0.951 (0.911-0.993) ** 0.022 




1.003 (0.953-1.056) ** 0.913 
* adjusted for age, BMI, tumour stage and smoking status 
**adjusted for age, BMI 
 
 
Stratification based on age at time of discontinued alcohol consumption was carried out and 
considered in relation to five categories: “never drinker”, “30-50 years”, “51-70 years”, “71-
99 years”, “continuous drinker”. By applying Kaplan-Meier analysis we were able to see a 





Figure 14. Survival distribution in EC patients with different alcohol consumption patterns 
 
Remarkably, continuous drinkers have a better prognosis than those who consume no alcohol 
whatsoever. However, there were relatively few people in the age groups that completely 
stopped alcohol consumption at a given point in time, which we believe may have an impact 
on the final results. Moreover, neither frequency of consumption nor quantity consumed 
impacted the likelihood of EC relapse or death among current drinkers. 
 
There was  a significant correlation between eating deep fried potatoes and consumption of 
bologna, sausage, and bacon (Spearman’s rho=0.339, p<0.001 and Spearman’s rho 0.285, 
p<0.001, respectively], which is likely evidence for a certain dietary trend. Similarly, soft 
drink consumption showed a positive correlation with eating white bread with jam 
(Spearman’s rho=0.212, p<0.001 and Spearman’s rho 0.199, p<0.001, respectively]. 
Although this last correlation is weak, it is interesting to note that these foods can be grouped 







Endometrial cancer is a common and complex gynecological disease that is currently of high 
relevance due to its increasing incidence. This thesis focuses on genetic susceptibility and 
prevalence of EC among LS families with an emphasis on mitochondrial activity and other 
risk factors, both known and unknown, that may impact this disease.  
 
5.1 STUDY I 
Is endometrial cancer a genetic disease?  
Our investigation of EC among selected groups of patients in Sweden, establishment of 
family history of cancer, and construction of pedigrees brings new insight into genetic 
predisposition to EC.  
 
In our study, 13% (64 patients) of index patients had at least one family member diagnosed 
with EC, more than half of them (7%) among first-degree relatives. Of these, 30 patients 
(47%) had family members who were diagnosed early in life, under age 50. Multiple cancers 
may be indicative of a hereditary cancer syndrome.  
In the modern medical era of advanced cancer genomics, the ability to recognize a possible 
familial cancer syndrome or genetic susceptibility can be crucial for cancer prevention.   
While there are known genetic mutations that affect the risk of breast and ovarian cancer 
(BRCA 1 and 2)[47] the genetic predisposition for EC other from LS or the rare Cowden 
syndrome, can be highly beneficial. In this regard, a number of studies have found that 
women with at least one first-degree relative with a history of EC are themselves at increased 
risk of developing this disease [51, 120-122]. 
 
In 2015, Win et al. [123] conducted a systemic review and meta analysis of 16 studies, 
including six cohort and ten case control studies. Of these, 13 studies reported an association 
between EC in the patient and a family history of EC among her first-degree relatives. Both 
genetic risk factors and confounding environmental risk factors, such as obesity, DM, and 
hormonal therapy, pose a challenge.   
An almost threefold risk of developing EC was found among first degree relatives of patients 
diagnosed with type I EC, as reported by Seger et al. [120]. The group also found more than 
a twofold risk among second-degree relatives to EC patients when comorbidity factors such 
as obesity were present, which suggests synergy between environmental factors and genetic 
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predisposition. The median BMI among our study participants was 26.6, with no significant 
difference between groups. 
 
Endometrial cancer and other cancers 
Among the family members of the index patients in our study, we found an increased relative 
proportion of laryngeal, stomach/unspecified abdomen, and skeletal cancers. To date, no 
known common genetic factor has been discovered that can explain a relationship to those 
cancers. But interestingly, a study focused on acrylamide [124] related dietary intake of this 
substance to a risk of developing other cancers such as EC, laryngeal, and stomach cancers. 
The high rate of skeletal cancer may possibly be in error and attributable to incorrectly 
diagnosing metastases as a primary cancer.  
 
A new breast cancer syndrome? 
Almost half of the index patients in our study were diagnosed with multiple cancers, 45% 
with both EC and breast cancer, which is higher than expected compared with other studies. 
Prior studies have suggested an association between these two cancers, regardless of family 
history.  A broad national study [125] including 37,583 women found no association between 
EC and family history of breast cancer, but did find a significant increase in risk of EC among 
women with a breast cancer diagnosis. The explanation may lie in use of medications such 
as unopposed estrogen as HRT, or adjuvant use of Tamoxifen for breast cancer, especially 
since Tamoxifen is known to increase the risk of EC [126] in postmenopausal women [127, 
128]. Even after adjusting for age and BMI, the latter risk persists, suggesting that it is 
predominantly due to  Tamoxifen intake [126]. 
While HRT combination therapy with dose-appropriate continuous progesterone 
administration may help protect against EC, treatment with unopposed estrogen or combined 
with insufficient progesterone is believed to increase this risk [129].  
 
Concomitant endometrial cancer and ovarian cancer. 
Conflicting results concerning a search for familial correlation between EC and ovarian 
cancer have been reported by various studies. In line with our own data, a comprehensive 
meta-analysis of nine studies showed no such association [123]. Ovarian cancer among 
family members of our index patients was present in 5% of the study population.  
However, Type II EC is also overrepresented among patients with BRCA 1/2 [130]. Uccella 
et al. reported that in most cases, the combination of ovarian and EC cancers can be explained 
by metastasis from the endometrium to the ovaries[131].  
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Concomitant endometrial and colorectal cancer 
Among our index patients with multiple primary cancers, 17% had both colorectal cancer 
and EC, though only in two women was there an association with LS. Despite our 
expectations of finding an association between EC and CRC, stemming from the well-known 
association seen in LS, no overrepresentation of CRC emerged. The finding of concomitant 
CRC in 17% of our index patients is considerably higher than the figure reported by Uccella 
et al. [131], who found only 3%. In addition, Uccella et al.  found that LS is the major risk 
factor for the association with CRC. In contrast, Delin et al. [132] reported findings more 
similar to our results, at 11% CRC.  When compared with the general population, the risk of 
EC patients for developing a secondary primary malignancy is elevated and correlates with 
a higher degree of histological differentiation [133]. 
 
Endometrial cancer and Lynch syndrome. 
Nine families (1.9%) in our study met the Amsterdam criteria, 7 of which had a verifiable LS 
mutation – the MSH2 mutation was found in 4 families, while 3 families had the MLH1 
mutation. No case with the MSH6 mutation was found in our study population, which may 
be because such cases are less likely to meet the Amsterdam II criteria [134, 135]. Otherwise, 
the distribution of mutations is in line with overall knowledge concerning a variety of 
mutations [136]. Since the Amsterdam II criteria are thought to be 60%-80% sensitive, the 
1.5% of LS cases found in our study likely represent an underestimate [137]; it would be 
especially easy to miss the MSH6 mutation.  
 
5.2 STUDY II 
The genome-wide association study (GWAS) is developed in order to identify heritability of 
complex genetic diseases in which many gene variants are causative[138]. All genetic 
material varies from individual to individual and a large part of the variation is in a single 
nucleotide variants[139]. Variations in a single nucleotide that exist in more than 1% of the 
population are called single nucleotide polymorphism, SNP[140]. The hypothesis behind 
GWAS is that common disorders are most probably determined by a common genetic 
variants, and SNPs are the most common type of variation studied by GWAS.  
To date, GWAS have identified 16 different risk regions associated with EC [55-57]. 
Additional studies have analyzed expression of trait loci and successfully identified a number 
of genes and genetic pathways involved in EC tumorigenesis. Furthermore, mendelian 
randomization methodology has confirmed that risk factors considered to be causal for EC, 
including BMI and early menarche, may actually be inherited with genetic implications 
 
58 
concerning risk for EC [55]. [55].  To differentiate between high-risk gene mutations, such 
as those seen in LS (MLH1, MSH2, or MSH6), The principle emerging from GWAS is that 
even though the risk of an individual genetic variation is only low or modest, the impact of 
those variations together could explain the risk for familial EC[54, 56, 141].  Many recent, 
GWAS studies provide support for the fact that common genetic variation that can influence 
the susceptibility to EC[142]. Common polygenic factors are assumed to increase the risk for 
EC, and could account for about 28% of the familial risk of EC[55]. The 16 identified genetic 
regions could explain approximately 7% of the polygenic risk[143].  
Our study shows for the first time an association between genetic variants in the TERT-
CLPTM1L region and risk for EC. We investigated this association, using the iCOGS array 
and genotype imputation, to study the risk of EC in a population of European descent. We 
identified 3 independent risk SNPs within the region. Wang et al. [67] notably in a 
significantly smaller study, investigated almost 2000 SNPs in the 5P15 region, no support 
emerged for the association that we found to EC. Prior to our study, GWAS did identify a 
risk association between the HNF1B locus and EC. Meanwhile, Sprudel et al. provided 
convincing evidence for an association between EC and SNP rs4430796, located near the 
HNF1B gene on chromosome 17q [53], which was later confirmed in a follow-up study 
investigating how altered HNF1B gene expression affects risk of EC [54, 144].  
 
Interestingly, some of those SNPs  and risk  regions were also associated with the risk of 
other hormone-sensitive cancers such as prostate [145], breast [146], and ovarian [147].   
Bafilgil et al [143] did not find an association to the TERT region but they did not include the 
same SNPs as ours in their analysis of polygenic risk score (PRS).  
 
Fine-mapping of genomic regions has its limitations due to the potential presence of multiple 
causal variants. However, we followed a previous suggestion [148] to use Bayesian inference 
instead of P-value and found an association with 2 of 3 SNPS, SNP 1 and 2. Thus, the results 
suggest an association between presence of SNPs 1 and 2 and risk of developing EC.  
 
The risk allele rs7705526 (set 1) is located within the TERT gene. Increased TERT promoter 
activity in both ER negative and ER positive breast and ovarian cancer has been reported by 
Bojesen et al. [147], as well as in EC [149]. Similarly, Cheng et al[150] has found association 




The rs13174814 (set 2) is located in the TERT promotor region. It has been shown to be 
associated with risk of gastrointestinal stromal cancer[151]. The rs13174814 has proven to 
affect binding of both RAD21, a gene encoding for repair protein,  and CTCF[152, 153]. Prior 
studies have demonstrated decreased expression of both RAD21 and CTCF with EC [154]. 
CTFC is thought to be a tumour suppressor, a chromatin remodeling and transcriptional 
factor[155].  
 
The third SNP associated with risk of cancer is rs62329728, which is located in the 
upstream/promoter region of CLPTM1L.  Evidence for an association between CLPTM1L 
and tumorigenesis is lacking, but in pancreatic cancer it is known to be associated with 
chromosomal instability [61]. [61]. Our analysis suggests differences in expression of 
CLPTM1L among different subtypes of EC; both TERT and CLPTM1L expression are 
increased in malignant tissues when comparing with the paired benign tissue sample.  
 
5.3 STUDY III 
One hallmark of tumor pathogenesis is metabolic alteration [156].  An important key 
regulator of mitochondrial biogenesis and function is transcriptional coactivator PGC1, 
which has been well studied, especially in healthy tissue, and is now considered to play a key 
role specifically as a regulator and promoter of oxidative metabolism [75].  However, its 
relationship to cancer is still under debate [157].  
 
Because PGC1  is central to mitochondrial biogenesis and crucial for metabolic 
programming and regulation, the question should be asked whether its function is reduced in 
cancer cells. In fact, evidence is growing supporting its role in tumorigenesis for a variety of 
hormone-related cancers [158]. But paradoxically, PGC1  is overexpressed in both breast 
and ovarian cancers [159]. 
 
PGC1 plays a complex part in its role as a master regulator and may potentially interact 
differently with various tissue-specific transcription factors in terms of outcome and function 
in relation to different types of cancer [160]. Our study found that expression of PGC1 is 
decreased in EC tissue compared with its benign counterpart, but no correlation between 
expression levels and tumor aggressiveness was found. Although we had expected to find a 
discrepancy in expression level because of the synergism suggested between estrogen and 
EC, expression was equally low regardless of EC tumor type [158]. 
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Interestingly, studies by both Ren et al. and Cormio et al. [161, 162] came up with results 
that contradicted those of our study. Ren et al., however, based their findings on a small 
cohort (n=15), and their expression levels in cancer were compared with a healthy control 
group, rather than a paired tissue sample. Moreover, Cormio et al. used a different technique, 
western blotting, to assess protein expression in heterogeneous extracts, while our study 
evaluated specific cancer cells. Results similar to ours, with lower expression of PGC1, 
were also demonstrated in other cancers, including clear cell ovarian cancer [76], colon [163], 
and breast [164].  
     
The flux of respiratory substrates occurs through the voltage-dependent anion channel, 
VDAC, which is localized to the outer membrane of the mitochondria [165], for which reason 
VDAC expression serves as an indicator for mitochondrial activity. 
 
As in the case of PGC1, VDAC expression was found to be lower among cancer cells 
compared with benign tissue. In line with the findings concerning PGC1 expression, here 
too, no discrepancy was seen between tumor types. Results concerning VDAC expression 
are inconsistent in different cancers and from different studies [166, 167]. In addition, there 
is no correlation between expression levels of VDAC and PGC1, one example being clear 
cell ovarian cancer [76]. Taken together, these inconsistencies indicate that the role and 
function of VDAC is highly dependent on specific cellular context, for which reason it has 
no value as an indicator of mitochondrial function. 
  
However, our finding of the correlation between low PGC1 expression and shorter time to 
death may hold potential clinical value, especially given that this observation was mainly 
noted in the FIGO stage I group, where patients were treated exclusively by surgery. Thus, 
should lower expression of PGC1 correlate with an increased risk for EC recurrence, a 
change in therapeutic strategy would be warranted. 
 
5.4 STUDY IV 
Diet has been clearly linked with modifying risk of cancer in general and gynecological 
cancer specifically. Other important risk factors include obesity and insulin resistance, which 
cause an increase in estrogen related to a mechanism by which aromatization of androgens 
to estrogens occurs in adipose tissue [1, 168]. The hyperinsulinemia resulting from a high 
glycemic index diet has been implicated in EC tumorigenesis [169], while the popular 
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ketogenic diet, on the other hand, has been associated with a beneficial effect in EC patients 
and has therefore been recommended for adjuvant therapy in this disease, as well as for other 
cancers [85, 170].  
 
Knowing this, we thought to search for a more specific dietary factor that could affect risk or 
influence disease progression in EC. To this end we used a machine learning approach known 
as Random Survival Forest to study dietary habits and activities of daily living among EC 
patients. We uncovered two factors – consumption of fried potatoes and carbonated soft 
drinks – that link to an increased risk of EC relapse and death, and one factor, physical 
activity, that improved patient prospects. 
  
The rate of EC recurrence has been linked to well-known individual and clinical parameters, 
including age, obesity, and tumor type. Moreover, it has been well demonstrated that 
endometrial proliferation is dependent on the balance of female sex hormones. In addition to 
such previously recognized risk parameters, our study showed that lifestyle habits, such as 
dietary preferences, also have an influence on ultimate risk of relapse. 
 
Fried food – rich in Acrylamide 
High acrylamide concentrations are known to be found in starchy foods that are prepared 
using high-temperature methods such as frying and roasting [171, 172]. Acrylamide is a vinyl 
monomer. Already in 1994 Acrylamide has been considered as “probably carcinogenic to 
humans” by International Agency for Research on Cancer Working Group. This decision was 
based on experimental studies in which animals were subjected to significantly higher 
acrylamide loads than those found in regular foods. In a 2019 statement, the FDA noted that 
acrylamide continues to be found in various foods, although levels had dropped somewhat 
since the last update, especially in  foods such as crackers and potato chips [173]. In Sweden, 
the National Food Agency has declared that acrylamide exposure is approximately 30-40 
𝜇g/per person per day, well below hazard level. Nevertheless, acrylamide has been implicated 
as a possible endocrine disrupter capable of altering hormonal balance even in small 
quantities [174-176], as suggested by one experiment on female rats that developed 
endometrial hyperplasia and uterine adenocarcinoma in response to glycidamide (epoxide 
metabolite of acrylamide) [177]. Since acrylamide intake is associated with alterations in sex 
hormone levels, this mechanism is thought to underlie the association with gynecological 
cancer, specifically through an increase in estradiol [86, 178]. A recent meta-analysis on 
dose-response pertaining to acrylamide intake found an increased risk, albeit small, of 
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developing EC [179]. The negative effects attributable to frying did not pertain to boiled or 
mashed potatoes, thereby suggesting that the specific cooking method was responsible for 




In the same meta-analysis [86], found that the correlation between high risk of developing 
EC and acrylamide intake was linear and stronger among never smokers than among 
smokers, an expected result since a number of studies have demonstrated a protective effect 
on risk of developing EC attributable to the antiestrogenic properties associated with smoking 
[180-182]. Nevertheless, among patients in our study the risk of death persisted even after 
adjustment for age, tumor stage, and smoking status and notably, smoking status per se had 
no effect on relapse or survival rate. 
 
Sugar-sweetened beverages (SSB) 
Our study found that consumption of carbonated soft drinks increases the risk of death among 
patients with EC. Insulin levels increase in response to consumption of sugar-sweetened 
beverages (SSBs). Insulin impacts EC in several known ways [183, 184]. First, insulin 
inhibits production of sex hormone-binding globulin (SHBG), which normally binds to 
circulating sex hormones [185]. This decrease in SHBG results in higher levels of bioactive 
free estrogen, which in turn induces endometrial proliferation [186]. Next, insulin may 
indirectly exert an apoptotic and mitogenic effect [187, 188] via insulin growth factor-1 (IGF-
1) which increases in the blood [189, 190] in response to elevated insulin. Inoue-Choi et al. 
[ref] assessed consumption of sugary foods and beverages (including SSBs) in 23,039 
postmenopausal women and found a positive association between SSB intake and increased 
risk of type I EC, an association that persisted even after adjusting for BMI, physical activity, 
smoking status, and history of diabetes [191]. Our findings regarding consumption of SSBs 
are in line with many prior studies, though it must be kept in mind that the ultimate results 
vary, likely due to differences in study design and variation in beverage sugar levels within 
the group. A recent dose-response meta-analysis found that when large (>50,000 participants) 
and prolonged (≥10 years follow-up) studies are included [192], there is an association 





Our study found that carbonated soft drinks significantly increased risk of death, but have no 
association with relapse of EC. One finding of notable interest is that the rate of relapse and 
death was unaffected by substitution of light carbonated soft drinks containing lower sugar 
levels or artificial sweeteners, perhaps because OS data include all-cause mortality, not just 
EC-related deaths. Given parameters such as old age and attendant inevitable comorbidities, 
SSB consumption may also have a considerable impact on other conditions, such as 
metabolic syndrome, and thereby via these mechanisms contribute to an increased mortality 
rate. This serves as a reminder that caution should be observed when speculating about the 
impact of various predictors on cancer-specific mortality. 
 
Physical exercise 
Beyond beneficial effects on obesity, diabetes, and cardiovascular disorders, regular physical 
activity reduces risk of developing several malignancies, including EC [193]. A meta-analysis 
by Moore et al. showed that active women were at 30% less risk of developing EC compared 
with their non-active counterparts [94]. A systematic review reported similar results and 
found that women who exercise regularly are at a 20-40% lower risk of developing EC [194]. 
Our study found no effect of physical activity on relapse of EC, but did show an association 
with decreased risk of death. Once again, due to the presence of multiple health issues among 
elderly patients, the effects of physical activity are ultimately related to a variety of 
mechanisms. Examples of benefits from physical activity include but are not limited to, 
normalization of insulin levels, decrease in inflammatory markers and reactive oxygen 
species, modulation of the immune system and, obviously, weight loss [195-197]. This last 
benefit results in depletion of adipose tissue, which causes less aromatization, and thereby 




Due to complicated and unequal distribution of data in our specifically related patient 
categories, as well as a paucity of relevant patients, we are unfortunately unable to draw any 
firm conclusions concerning the effects of discontinuing alcohol consumption on PFS and 
OS in patients with EC. When assessing the average quantity of alcohol consumed in relation 
to patient outcomes, we found no statistically significant differences. More parameters 






Some inaccuracies in our data may stem from errors made by patients when completing the 
questionnaires. Nevertheless, because patients were given adequate time to fill out the 
questionnaires, there were very few missing data, which  is a testament to the reliability of 
this approach. Many studies focus on investigating food products or activities that may 
impact risk of developing EC. Our study, however, took a retrospective approach in studying 
patients who had already undergone surgical treatment for EC. Therefore, due to differences 
in study perspectives, some outcomes may not be the same. Our results, however, are aligned 
with previous major findings, implying at least some commonality in how cancers initially 





6. METHODOLOGICAL CONSIDERATION 
6.1 STUDY DESIGN 
Study I-IV were retrospective observational cohort studies in which data were collected from 
questionnaires and medical records, and subsequently confirmed through patient interviews. 
Observational studies are somewhat limited by the quality of evidence obtained compared 
with that in a randomized study, though we partially compensated for this by having a large 
cohort. Nevertheless, the three studies in this thesis share one major strength: data were 
collected from electronic medical records, in which information was recorded by pathologists 
following the same structural procedures. Study I sourced its information from the well-
controlled data of the Swedish cancer registry, while the general population served as our 
control group. One and the same person systematically conducted all phone interviews, 
thereby decreasing risk of selection bias and recall bias. However, we were, of course, 
dependent on how precisely healthcare providers entered relevant information into the 
medical records system. 
In our opinion, study IV was strengthened by the relatively large number of participants, 
lengthy monitoring periods, and an extensive set of assessed parameters. Moreover, the 
Random Survival Forest is considered to be an effective approach to data analysis involving 
high dimensional datasets with limited survival data. Despite this, it must be acknowledged 
that certain confounding factors may have escaped our scrutiny, even if they potentially 
influenced findings. 
 
One limitation of study I was family pedigree construction based solely on patient-provided 
information, obviously entailing a risk of recall bias. To counter this, we confirmed the 
information provided using the Swedish cancer registry. 
 
Study III may be limited by a lack of external validation since the paired control tissue 
samples were obtained from the same patient, and in retrospect it would be impossible to 
exclude the possibility that healthy tissue in close proximity to the tumor tissue could have 
harbored subtle precancerous molecular changes.   
 
Recall bias is a likely limitation of study IV since patients were asked to complete 
questionnaires concerning lifestyle factors which they may have remembered imperfectly, or 
perhaps did not want to report accurately.  
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6.2 SYSTEMATIC AND RANDOM ERRORS 
Both systematic and random errors may be associated with epidemiological studies. The risk 
of systematic errors, for example, is higher in observational studies, where selection bias, 
information bias, and confounding factors may intervene. 
6.2.1 Selection bias 
Given the study population, the exposure-outcome association should be fairly consistent. 
Where exposure and outcome differ, it is likely that the sample under study did not accurately 
reflect the target population, known as selection bias.  
Selection bias in our studies, primarily studies, I II, and IV should be low since our data were 
collected from consecutive patients with EC who had surgery at Karolinska Hospital. 
However, concerning study III, one group of patients had to be chosen from a larger cohort, 
in which all patients with  type II, recurrent disease/death  were selected and matched with a 
control group.  
6.2.2 Information bias 
Another name for information bias is misclassification. When evaluating the relationship  
between exposure and outcome, it is important to avoid inaccurately representing or 
classifying either exposure or outcome. When misclassification is evenly distributed across 
the entire study group, it is referred to as random or non-differential, but when unevenly 
distributed across the study group, it is considered to be differential. Non-differential 
misclassification is associated with results that reduce the differences between groups and 
underestimate the true association, while differential misclassification may result in a false 
association in either direction.  
 
One common cause of differential misclassification is patients lost to follow-up, which did 
not occur in our study, as follow-up among all cohorts was sustained. However, studies I and 
III were limited by another type of differential misclassification, namely recall bias. Recall 
bias in study I results from either lack of information, or misleading information, provided 
by patients regarding their family history. A parallel situation occurs in study III, where recall 








Confounding, a well-known challenge in epidemiologic research, is a third problem that may 
adversely impact the association between exposure and outcome. Although confounding 
cannot be eliminated from observational studies, its impact can be reduced through 
stratification, matching, restriction, or by multivariable analysis. In randomized studies, 
confounders can be controlled through equal distribution within the study population. Due to 
the large quantity of data, many confounding factors may occur in the studies. We attempted 
to overcome these by applying statistical analyses and stratification to a variety of relevant 
factors.  
6.2.4 Random error 
Random errors may occur when variability within the data occur by chance. The risk of 
random errors decreases as the study population increases. Confidence intervals (CI) of 95% 
are generally used to calculate risk which means that the observed association has a 95% 
probability of not being due to chance as long as the CI does not include 1.00 and that no 
systematic errors have occurred. A wide CI translates to lower precision, whereas a narrow 
CI indicates less variability in the data.  
 
P-value is a number between 0 and 1 that indicates how compatible the study results are with 
the null hypothesis. A p-value <0.05 is considered significant; the lower the P-value, the 
stronger the evidence against the null hypothesis. 
We did calculate p-Value in order to avoid random error.  
6.3 EXTERNAL VALIDITY 
External validity is a reflection of how well the study results could be generalized to other 
populations. Internal validation refers to the probability that an observed situation is correct, 
the higher the internal validation, the more generalizable the results to other populations. 
Internal validation is optimized by reducing or completely eliminating bias. The degree of 
similarity between populations is highly relevant to the concept of external bias. An example 
of internal validation is that in Study III, there we blindly to clinical outcome evaluated the 
samples by two independent observers. The degree of similarity between the populations is 
extremely relevant in the discussion of an external bias. In study I for example we compered 
our population to the registry of both 1970 and 2010 in order to validate our result and 

















































• Overrepresentation of EC among first and second-degree relatives and first cousins 
of endometrial cancer patients compared with the general population.  
• Multiple cancers and young age of onset in families with EC strengthen the case for 
existence of an additional hereditary EC syndrome.  
• The prevalence of LS was about 2%.  
• Only one of seven mutation-verified LS families had been previously diagnosed. 
• Importance of appropriate diagnosis and referral for genetic counseling and better 
follow-up of individuals at high risk of EC.  
 
Study II: 
• A novel risk locus for EC has been uncoverd. 
• Three novel independent varients within 5p15 locus that increase the risk developing 
EC. 
• Over expression of TERT among EC patients, suggesting a potential role in 
tumourogenesis. 
• About 0.5% of the relative risk for familal cancer may be attributable to our findings. 
 
Study III: 
• Downregulation of PGC1 was observed in endometrial cancer tissue in both types. 
• Downregulation of VDAC1 protein levels indicating an altered mitochondrial 
function in the cancer tissue compared with benign tissue. Also found in both types. 
• An interesting tendency toward an association between lower PGC1 expression 
among Stage I FIGO and shorter time to death. This could be of high clinical value 












• Using the Random Survival Forest algorithm, we observed that fried potato 
consumption significantly increases the risk of EC relapse and death. 
• This effect persists after adjustment for age, BMI, stage, and smoking status. 
• Sugar-sweetened beverage consumption significantly reduces OS, but has less impact 
on EC relapse.  
• Physical activity is associated with a lower risk of death among patients with EC; the 
effect persists after adjustment for age and BMI.  
• Our findings suggest that dietary modification may be beneficial in patients with EC; 






8. FUTURE PROSPECTIVES 
 
• Further studies on constructing a family history of cancers to assess for a possible 
endometrial cancer syndrome are underway, including application of next-generation 
sequencing in a study population with positive family history.  
• To further elucidate the functional effects of TERT/CLPTM1L variants on EC and 
other hormone-related cancers, additional biological studies will be required on these 
variants. Future gene studies concerning the role of other multicancer loci would also 
seem appropriate. 
• GWAS using resequencing may have the potential to identify additional low 
frequencey causal variants. 
• Further develop a new model for the persononalized risk assesment using PRS in 
combination with life style and clinical measures.  
• Studies aimed at understanding the exact nature and role of PGC1 in endometrial 
cancer are needed, since findings so far are contradictory. A larger cohort study is 
suggested; the same applies to VDAC. 
• Should lower expression of PGC1 in EC correlate with increased risk of recurrence, 
it could find clinical use as a marker.  
• Different molecular markers that can be assessed during endometrial biopsy need to 
be further studied so as to optimize treatment and thereby reduce recurrence and 
increase OS. 
• Due to the nature of questionnaires, they may be associated with a risk of bias. To 
eliminate such bias, a prospective study on dietary modification could be conducted 
on EC patients to evaluate the correlation between dietary habits and recurrent EC, as 















































SAMMANFATTNING PÅ SVENSKA 
 
Livmoderskroppcancer (endometriecancer) är en av de vanligaste gynekologiska 
cancerformerna och den sjätte vanligaste cancerdiagnosen hos kvinnor totalt sett. Incidensen 
har ökat under de senaste decennierna och år 2020 drabbades 1400 kvinnor i Sverige av 
sjukdomen. 
Överlevnaden i livmoderkroppscancer är god tack vare att symtomen av sjukdomen debuterar 
tidigt i förloppet, vilket gör att de flesta som insjuknar upptäcks i ett tidigt skede. Idag är 
femårsöverlevnaden i sjukdomen cirka 85%. 
Livmoderkroppscancer är en komplex sjukdom som har många olika riskfaktorer. Sjukdomar 
som fetma, diabetes och högt blodtryck är bland de vanligaste och de mest välkända 
riskfaktorerna.  Även höga östrogennivåer, både externt intag eller kroppsegen produktion 
kan bidra till utveckling av livmoderkroppscancer. 
Ärftliga cancersyndrom som oftast beror på mutationer i DNA:s reparationsgener, 
exempelvis Lynch Syndrom, har visat sig ha en hög risk för utveckling av 
livmoderkroppscancer. Hos Lynch Syndrom patienter har man sett en kraftigt ökad risk för 
tjocktarmscancer och livmoderkroppscancer med en livstidsrisk på ca 50% att utveckla 
sjukdomen. 
 
I studie I ville vi studera om det kan finnas andra ärftliga faktorer förutom redan kända 
ärftliga cancersyndrom, som ökar risken för utveckling av livmoderkroppscancer hos vissa 
patienter. I vår studiepopulation sågs en ökad risk för insjuknande i livmoderkroppscancer 
hos individer med första eller andragradssläktingar som också haft sjukdomen jämfört med 
normalpopulationen, samt att de insjuknade i en tidigare ålder. Bland dessa individer kunde 
inga kända cancersyndrom verifieras.  
 
I studie II ville vi studerade om TERT-CLPTM1L genen är associerad med ökad risk för 
endometriecancer. Studiemetoden var en Genom Wide Association Study (GWAS). Vi 
hittade en association mellan tre tidigare ej kända riskloci som ligger i närheten eller i själva 
området för TERT-CLPTM1L och ökad endometriecancer förekomst. Enligt våra 
estimeringar är dessa tre locus associerade med ungefär 0. 5% av alla fall med familjär 
endometriecancer.   
 
I studie III ville vi studera uttrycket av de specifika mitokondrieproteinerna PGC1 och 
VDAC1 i tumörvävnad. Mitokondrier kallas oftast för cellens kraftverk eftersom de är 
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ansvariga för cellens energiproduktion. Mitokondrierna har därför en huvudroll i 
cancerceller, då de driver och effektiviserar deras höga energiproduktion. Vi ville därför se 
om det fanns en koppling mellan nivåerna av PGC1 och VDAC1 och tumörens kliniska 
karaktär. Vi har kunnat påvisa att båda proteinerna hade ett ökat uttryck i malign vävnad 
jämfört med benign vävnad. Vidare, vi observerade icke signifikant korrelation mellan lågt 
PGC1a-uttryck och kortare tid till döden bland patienter med endometriecancer i stadium 1. 
Denna korrelation har ett kliniskt värde eftersom dessa patienter endast behandlas med 
kirurgi. Om ett lägre uttryck av PGC1a är korrelerat med ökad risk för återfall kan en annan 
terapistrategi vara aktuell.  
 
I studie IV har vi studerat om kost påverkar utvecklingen av livmoderkroppscancer. 
Patienterna svarade på en enkät med frågor om kostvanor. Patienter med ett högt intag av 
friterad potatis samt söt kolsyrad dryck hade båda en signifikant ökad risk för återfall och 
dödlighet i livmoderkroppscancer. Vi rekommenderar därför att man inte bara ser på 
kostvanor som en riskfaktor att få sjukdomen, utan också som ett verktyg för att optimera 
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